Document:

EX-10.2

Exhibit 10.2

CONAGRA FOODS, INC.

2014 EXECUTIVE INCENTIVE PLAN

 

1. Purpose.  The principal purposes of the ConAgra Foods, Inc. 2014 Executive Incentive
Plan (the “Plan”) are to provide incentives to participating eligible officers of the Company who
have significant responsibility for the success and growth of the Company, to assist the Company in
attracting, motivating and retaining such officers on a competitive basis and to potentially
preserve the tax deductibility of incentive awards paid to eligible officers under Section 162(m)
of the Code (as defined below).

2. Definitions. 

a. “Board” means the Board of Directors of ConAgra Foods, Inc.

b. “Code” means the Internal Revenue Code of 1986, as now in effect or as hereafter amended
from time to time. (All citations to Code sections are to such sections as they are currently
designated and any reference to such sections shall include the provisions thereof as they may from
time to time be amended or renumbered as well as any successor provisions and any applicable
regulations.)

c. “Committee” means the Human Resources Committee of the Board, or its successor, or such
other committee of the Board to which the Board delegates power to act under or pursuant to the
provisions of the Plan. Each member of the Committee shall qualify as (i) an “outside director”
for purposes of Code Section 162(m), (ii) a “non-employee director” for purposes of Rule 16b-3 of
the Securities Exchange Act of 1934, as amended, and (iii) “independent” for purposes of any rules
and regulations of the stock exchange or other recognized market or quotation system on which the
common stock of ConAgra Foods, Inc. is principally traded or quoted at the relevant time, except
that the Board may determine to have these qualification requirements satisfied by a subcommittee
of the Committee (and, in this case, any reference to “Committee” in the Plan shall be deemed to be
a reference to this subcommittee to the extent necessary to satisfy these requirements).

d. “Company” means ConAgra Foods, Inc. and each of its Subsidiaries.

e. “ConAgra Foods, Inc.” means ConAgra Foods, Inc., a Delaware corporation and its successor
and assigns.

f. “Eligible Officer” means an employee of the Company who is considered an officer of ConAgra
Foods, Inc. within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder, and senior officers and other employees of
the Company performing similar duties for ConAgra Foods, Inc., in either case, who are selected by
the Committee for participation in the Plan.

g. “Fair Market Value” means, on any date, the closing price of the common stock of ConAgra
Foods, Inc. as reported on the New York Stock Exchange (or on such other recognized market or
quotation system on which the trading prices of the common stock are traded or quoted at the
relevant time) on such date. In the event that there are no stock transactions reported on such
exchange (or such other system) on such date, Fair Market Value means the closing price on the
immediately preceding date on which stock transactions were so reported. The Committee is
authorized to adopt another Fair Market Value pricing method provided such method is in compliance
with the fair market value pricing rules set forth in Code Section 409A.

h. “Participant” means an Eligible Officer participating in the Plan for a performance period
as provided in Sections 5 or 6.

i. “Plan” means this ConAgra Foods, Inc. 2014 Executive Incentive Plan, as amended or amended
and restated from time to time.

j. “Qualified Performance-Based Award” means an award (or a specified portion of an award) to
an Eligible Officer under the Plan that is intended to satisfy the requirements for “qualified
performance-based compensation” under Code Section 162(m).

k. “Subsidiary” means any corporation, partnership, joint venture or other entity in which
ConAgra Foods, Inc. owns, directly or indirectly, 25% or more of the voting power or of the capital
interest or profits interest (within the meaning of Code Section 414(c)) of such entity.

3. Administration of the Plan. The Committee shall have full power and authority to
administer and interpret the Plan and to adopt such rules, regulations and guidelines for the
administration of the Plan and for the conduct of its business as the Committee deems necessary or
advisable.  The Committee’s interpretations of the Plan, and all actions taken and determinations
made by the Committee pursuant to the powers vested in it hereunder, shall be conclusive and
binding on all parties concerned, including the Company, its stockholders and any person receiving
an award under the Plan. The Committee may delegate its responsibilities under the Plan to such
individuals, including members of management, as the Committee may appoint, provided that no
delegation shall be made with respect to an opportunity to receive either a Qualified
Performance-Based Award to the extent it would cause such award to fail to qualify under Code
Section 162(m), or any award to the extent it would cause such award to fail to meet any other
requirements referenced in the definition of “Committee” that are applicable to the award. No
member or former member of the Committee or the Board shall be liable for any action or
determination made in good faith with respect to the Plan or any award granted under it.

4. Eligibility.  All Eligible Officers are eligible to participate in the Plan for any
performance period. For each performance period, the Committee, in its discretion, shall select
the Eligible Officers who shall participate in the Plan. No Eligible Officer is guaranteed to be
eligible to participate for any performance period and an Eligible Officer who is selected by the
Committee for participation in one performance period may be excluded from participation in any
subsequent performance period.

5. Awards.

a. Establishment of Awards. For each award under the Plan, the Committee shall specify: (i)
the incentive award performance goal(s), which may vary by Participant or by groups of
Participants, and which shall be used to determine the compensation payable under the award; (ii)
the performance period over which performance shall be determined in connection with the
performance goal(s); and (iii) the maximum compensation that may be paid in connection with the
award upon the achievement of the specified performance goal(s) during the performance period.
Subject to the maximum specified, the Committee may provide for a threshold level of performance
below which no amount of compensation will be paid, and it may provide for the payment of differing
amounts of compensation for different levels of performance. The performance period for an award
may be a fiscal year, or it may be a period that is shorter or longer than a fiscal year. The
Committee may grant awards subject to performance goals that are either Qualified Performance-Based
Awards or are not Qualified Performance-Based Awards. In the case of a Qualified Performance-Based
Award, the Committee shall establish in writing the terms described in this paragraph not later
than required by Code Section 162(m).

b. Performance Measures/Goals.

i. The performance measure(s) with respect to a Qualified Performance-Based Award under
the Plan shall consist of one or more or any combination of the following performance
measures: cash flow; free cash flow; operating cash flow; earnings; market share; economic
value added; achievement of annual operating budget; profits; profit contribution margins;
profits before taxes; profits after taxes; operating profit; return on assets; return on
investment; return on equity; return on invested capital; gross sales; net sales; sales
volume; stock price; total stockholder return; dividend ratio; price-to-earnings ratio;
expense targets; operating efficiency; customer satisfaction metrics; working capital
targets; the achievement of certain target levels of innovation and/or development of
products; measures related to acquisitions or divestitures; formation or dissolution of joint
ventures; corporate bond rating by credit agencies; debt to equity or leverage ratios; or
financial performance measures determined by the Committee that are sufficiently similar to
the foregoing as to be permissible under Code Section 162(m).

ii. If more than one individual performance measure is specified by the Committee in
defining performance goals for a Qualified Performance-Based Award, the Committee shall also
specify, in writing, whether one, all or some other number of such performance goals must be
attained in order for the performance measures to be met. With respect to any award that is
not intended to be a Qualified Performance-Based Award, the Committee may use performance
measures that are different than those set forth above.

iii. Each performance goal may be described in terms of Company-wide objectives or
objectives that are related to the performance of the individual Participant or of one or
more of the Subsidiaries, divisions, departments, regions, functions or other organizational
units within the Company. Each performance goal may be based upon growth, may be made
relative to the performance of other companies or subsidiaries, divisions, departments,
regions, functions or other organizational units within such other companies, may be made
relative to an index or one or more of the performance goals themselves, may be based on or
otherwise employ comparisons based on internal targets or the past performance of the
Company, and in the case of earnings-based measures, may use or employ comparisons relating
to capital, stockholders’ equity and/or shares outstanding, investments or assets or net
assets. The specific performance goal(s) and measure(s) for each Qualified Performance-Based
Award shall be established in writing by the Committee within ninety days after the
commencement of a performance period (or within such other time period as may be required by
Code Section 162(m)) to which the performance goal(s) relates or relate. In the case of a
Qualified Performance-Based Award, each performance goal will be objectively determinable to
the extent required under Code Section 162(m).

c. Payment of Awards. Awards shall be payable following the completion of each performance
period (unless deferred consistent with Code Section 409A), and, for Qualified Performance-Based
Awards, only after certification in writing by the Committee that the specified performance goal(s)
established under the Plan was or were achieved (and with any earnings on a deferred award limited
as required to comply with Code Section 162(m)). Unless the Committee specifies otherwise in the
terms of an award, payment shall be made on or before the later of (a) the fifteenth day of the
third month that begins after the month containing the end of the applicable fiscal year (with the
applicable fiscal year being the fiscal year containing the end of the performance period for which
performance is certified), or (b) the fifteenth day of the third month that begins after the end of
the Participant’s tax year that contains the end of the performance period for which performance is
certified. Awards may be paid in cash or securities. If an award is paid in securities, such
payment shall be accomplished by a grant under a ConAgra Foods, Inc. plan that expressly provides
for making grants of securities. Subject to the terms of such plan, grants or awards of stock
options or stock appreciation rights shall be based on a stock price that is not less than the Fair
Market Value on the date of grant.  Notwithstanding the attainment of the specified performance
goal(s), the Committee has the discretion, for each Participant, to reduce some or all of an award
that would otherwise be paid.

d. Maximum Awards. Any provision of this Plan notwithstanding, in no event may any Participant
earn an aggregate award under this Plan in any fiscal year in excess of $20,000,000 (such maximum
award amount to be proportionately adjusted for performance periods that are shorter or longer than
a 12-month fiscal year, with multiple incentive opportunities considered in the aggregate in the
case where multiple, overlapping performance periods are established hereunder).

e. Adjustments. In determining whether any performance goal(s) has or have been satisfied with
respect to Qualified Performance-Based Awards, the Committee may exclude the effect of (i) any or
all extraordinary items (as determined under U.S. generally accepted accounting principles), and
(ii) any other unusual or nonrecurring items or events, including but not limited to: (A) charges,
costs or benefits or gains associated with: restructurings of the Company; litigation or claim
adjudication, judgments or settlements; mergers, acquisitions, or divestitures; and material
changes in business, operations, corporate or capital structure; (B) foreign exchange or
hedge-related gains and losses; (C) asset write-downs; (D) discontinued operations; and (E) the
cumulative effects of accounting changes. In the case of Qualified Performance-Based Awards, the
exclusions and adjustments allowed by this Section 5(e) may only apply to the extent the Committee
specifies in writing (not later than the time performance goals are required to be established)
which exclusions and adjustments the Committee will apply to determine whether a performance goal
has been satisfied, as well as an objective manner for applying them, or to the extent that the
Committee otherwise determines that they may apply without adversely affecting the award’s status
as a Qualified Performance-Based Award. To the extent that a performance goal is based on an
increase in the stock price of ConAgra Food, Inc.’s common stock, then in the event of any stock
dividend, stock split, combination of shares, recapitalization or other change in the capital
structure of the Company, any merger, consolidation, spin-off, reorganization, partial or complete
liquidation or other distribution of assets (other than a normal cash dividend), issuance of rights
or warrants to purchase securities or any other corporate transaction having an effect similar to
any of the foregoing, the Committee shall make or provide for such adjustments in such performance
goals as the Committee in its sole discretion may in good faith determine to be equitably required
in order to prevent dilution or enlargement of the rights of Participants. In the case of a
Qualified Performance-Based Award, this adjustment shall apply only to the extent the Committee
determines it will not adversely affect the award’s status as a Qualified Performance-Based Award.

6. Special Rules. The Committee may establish rules and procedures for cases where
employment or eligibility begins after the start of a performance period, or ends before payment of
an award, to the extent they are consistent with the following:

a. Newly Hired Officer. In the case of an Eligible Officer who is hired by the Company after
the beginning of a performance period, the Committee may in its discretion designate such newly
hired Eligible Officer as a Participant for that performance period, provided that the newly hired
Participant may be granted a Qualified Performance-Based Award only to the extent the Participant’s
period of service during the performance period would not cause the performance goal(s) for such
award to be established later than permitted under Code Section 162(m).

b. Newly Eligible Officer. An Eligible Officer who is promoted, transferred or otherwise
changes positions and who becomes a Participant during the performance period may, at the
discretion of the Committee and under such rules as the Committee may from time to time prescribe,
be eligible for an award provided that a promotion or job change cannot (i) increase the amount
payable under a Qualified Performance-Based Award as a result of satisfying the performance goal(s)
that is or are intended to satisfy Code Section 162(m), or (ii) cause the performance goal(s) for a
Qualified Performance-Based Award to be established later than permitted under Code Section 162(m).

c. Termination of Employment. If an Eligible Officer terminates employment with the Company
prior to the end of a performance period, the terms of the award or the rules established by the
Committee shall apply to determine whether such award is forfeited or paid in whole or in part;
provided, however, that no Qualified Performance-Based Award shall be paid in whole or in part
prior to or without regard to certification of attainment of the performance goal(s).

7. Miscellaneous Provisions.  The Company shall have the right to deduct from the payment
of all awards hereunder any federal, state, local or foreign taxes required by law to be withheld
with respect to such awards. Neither the Plan nor any action taken hereunder shall be construed as
giving any Eligible Officer any right to be retained in the employ of the Company or in any
specific position with the Company. The costs and expenses of administering the Plan shall be
borne by the Company and shall not be charged to any award or to any Participant receiving an
award. Neither an award nor any other right or benefit under this Plan shall be subject to
alienation, sale, assignment, pledge, encumbrance or charge, and any attempt to alienate, sell,
assign, pledge, encumber or charge the same shall be void and shall not be recognized or given
effect by the Company. The Plan shall be construed and administered in accordance with the laws of
the State of Delaware.

8. Effective Date, Amendments and Termination.  The Plan will become effective on the date
on which such Plan is approved by the stockholders of ConAgra Foods, Inc. (provided that such
approval occurs on or before June 30, 2015). The Plan has been adopted and approved by the Board,
subject to, and to be effective upon, approval by ConAgra Foods, Inc.’s stockholders, which
approval is expected to be received at the 2014 annual meeting of ConAgra Foods, Inc.’s
stockholders. If such stockholder approval is not obtained on or before June 30, 2015, the Plan
shall terminate after such date and be of no further effect.

The Committee may at any time terminate or from time to time amend the Plan in whole or in
part, but no such action shall adversely affect any rights or obligations with respect to any
awards theretofore made under the Plan, except with the consent of the Eligible Officer granted the
award or to the minimum extent necessary to comply with applicable law.  No such amendment or
modification, however, may be effective without approval of the stockholders of ConAgra Foods, Inc.
if such approval is necessary to comply with the requirements of Code Section 162(m), including
(a) any change to the requirements as to eligibility for participation in the Plan, (b) any change
to the performance measures permissible under the Plan for payment of awards or (c) any increase to
the maximum amount that may be paid to a Participant for any period under Section 5(d). The Plan
shall continue in effect until terminated hereby or by the Committee.

9. Code Section 409A. Unless the Committee expressly determines otherwise, awards are
intended to be exempt from Code Section 409A as short-term deferrals and, accordingly, the terms of
any awards shall be construed and administered to preserve such exemption. To the extent the
Committee determines that Code Section 409A applies to a particular award granted under the Plan,
then the terms of the award shall be construed and administered to permit the award to comply with
Code Section 409A, including, if necessary, by delaying the payment of any award payable upon
separation from service to a Participant who is a “specified employee” (as defined in Code Section
409A and determined consistently for all Company arrangements that are subject to Code Section
409A), for a period of six months and one day after such Participant’s separation from service (as
defined in Code Section 409A, but treating the Company as constituting a single service recipient
unless the Committee timely provides otherwise). In the event anyone is subject to income
inclusion, additional interest or taxes, or any other adverse consequences under Code Section 409A
(“Non-compliance”), then neither the Company, the Committee, the Board nor its or their employees,
designees, agents or contractors shall be liable to any Participant or other persons in connection
with any Non-compliance, except to the extent the Non-compliance was the direct result of any
Company action or failure to act that was undertaken in bad faith.EX-10.45

 Exhibit 10.45 

Execution Version 
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES 

by and between 
 POZEN INC.

 and 
 ASTRAZENECA AB

 November 18, 2013 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH
HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 TABLE OF CONTENTS

  

									
	 	 	 	  	 	  	Page	 
			
	1.	 	DEFINITIONS	  	 	1	  
			
	2.	 	COLLABORATION GOVERNANCE	  	 	11	  
				
		 	2.1	  	Establishment	  	 	11	  
				
		 	2.2	  	Membership and Procedures	  	 	12	  
				
		 	2.3	  	Decision-Making	  	 	13	  
				
		 	2.4	  	Operating Principles	  	 	14	  
			
	3.	 	[Intentionally Omitted]	  	 	14	  
			
	4.	 	REGULATORY MATTERS	  	 	14	  
				
		 	4.1	  	Responsibilities; Diligence	  	 	14	  
				
		 	4.2	  	Access to Filings	  	 	14	  
				
		 	4.3	  	Interactions with Regulatory Authorities	  	 	14	  
				
		 	4.4	  	Exchange of Know-How; Information Sharing	  	 	15	  
				
		 	4.5	  	Regulatory Audits	  	 	15	  
				
		 	4.6	  	Adverse Event Reporting	  	 	16	  
				
		 	4.7	  	Records and Reports	  	 	16	  
			
	5.	 	DEVELOPMENT AND COMMERCIALIZATION	  	 	16	  
				
		 	5.1	  	Development and Commercialization	  	 	16	  
				
		 	5.2	  	Regulatory Obligations during Commercialization	  	 	16	  
				
		 	5.3	  	Performance; Diligence	  	 	16	  
				
		 	5.4	  	Threatened Removal	  	 	17	  
				
		 	5.5	  	Compliance	  	 	17	  
				
		 	5.6	  	Branding; Trademarks; Domain Names; Trade Dress; Logos	  	 	17	  
				
		 	5.7	  	Commercial Supply	  	 	18	  
			
	6.	 	[Intentionally Omitted]	  	 	18	  
			
	7.	 	LICENSES	  	 	18	  
				
		 	7.1	  	Licensed Technology	  	 	18	  
				
		 	7.2	  	Trademarks	  	 	18	  

 TABLE OF CONTENTS (cont’d) 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH
AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

									
	 	 	 	  	 	  	Page	 
				
		 	7.3	  	Sublicenses	  	 	18	  
				
		 	7.4	  	Reservation of Rights; No Implied Licenses	  	 	19	  
				
		 	7.5	  	Restrictive Covenant	  	 	19	  
			
	8.	 	FINANCIAL TERMS	  	 	20	  
				
		 	8.1	  	Royalties	  	 	20	  
				
		 	8.2	  	Payments and Sales Reporting	  	 	21	  
				
		 	8.3	  	Records; Audit	  	 	22	  
				
		 	8.4	  	Taxes	  	 	22	  
			
	9.	 	INTELLECTUAL PROPERTY	  	 	23	  
				
		 	9.1	  	Prosecution and Maintenance of Licensed Patents	  	 	23	  
				
		 	9.2	  	Prosecution and Maintenance of Joint Patents	  	 	23	  
				
		 	9.3	  	Ownership of Inventions	  	 	23	  
				
		 	9.4	  	Disclosure	  	 	24	  
				
		 	9.5	  	Cooperation	  	 	24	  
				
		 	9.6	  	Enforcement of Licensed Patents	  	 	24	  
				
		 	9.7	  	Defense of Infringement Claims	  	 	25	  
				
		 	9.8	  	Patent Term Extension and Supplementary Protection Certificate	  	 	26	  
				
		 	9.9	  	Consequence of Patent Challenge	  	 	26	  
				
		 	9.10	  	Patent Certifications	  	 	26	  
				
		 	9.11	  	Patent Marking	  	 	27	  
			
	10.	 	REPRESENTATIONS, WARRANTIES; COVENANTS	  	 	27	  
				
		 	10.1	  	POZEN Representations and Warranties	  	 	27	  
				
		 	10.2	  	Reciprocal Representations and Warranties	  	 	27	  
				
		 	10.3	  	DISCLAIMER OF WARRANTY	  	 	27	  
				
		 	10.4	  	POZEN Non-Compete	  	 	27	  
				
		 	10.5	  	Other Covenants	  	 	28	  

  
 -ii- 

 TABLE OF CONTENTS (cont’d) 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH
AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

									
	 	 	 	  	Page	 
			
	11.	 	CONFIDENTIALITY	  	 	28	  
				
		 	11.1	  	Definition	  	 	28	  
				
		 	11.2	  	Exclusions	  	 	28	  
				
		 	11.3	  	Disclosure and Use Restriction	  	 	29	  
				
		 	11.4	  	Authorized Disclosure	  	 	29	  
				
		 	11.5	  	Use of Name	  	 	30	  
				
		 	11.6	  	Press Releases	  	 	30	  
				
		 	11.7	  	Terms of Agreement to be Maintained in Confidence	  	 	31	  
			
	12.	 	TERM AND TERMINATION	  	 	31	  
				
		 	12.1	  	Amended and Restated Effective Date	  	 	31	  
				
		 	12.2	  	Term	  	 	31	  
				
		 	12.3	  	Termination for Material Breach	  	 	31	  
				
		 	12.4	  	Termination for Cause	  	 	32	  
				
		 	12.5	  	Consequences of Expiration and Termination	  	 	32	  
				
		 	12.6	  	Termination for Insolvency	  	 	32	  
				
		 	12.7	  	Effect of Bankruptcy	  	 	32	  
				
		 	12.8	  	Formulation Technology	  	 	33	  
				
		 	12.9	  	Survival	  	 	33	  
			
	13.	 	INDEMNIFICATION AND INSURANCE	  	 	34	  
				
		 	13.1	  	Indemnification by POZEN	  	 	34	  
				
		 	13.2	  	Indemnification by Licensee	  	 	34	  
				
		 	13.3	  	Indemnification Procedure	  	 	34	  
				
		 	13.4	  	Expenses	  	 	36	  
				
		 	13.5	  	Insurance	  	 	36	  
			
	14.	 	LIMITATION OF LIABILITY	  	 	36	  
			
	15.	 	MISCELLANEOUS	  	 	36	  
				
		 	15.1	  	Assignment	  	 	36	  

  
 -iii- 

 TABLE OF CONTENTS (cont’d) 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH
AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

									
	 	 	 	  	 	  	Page	 
				
		 	15.2	  	Termination of Certain Rights Upon POZEN Change of Corporate Control	  	 	37	  
				
		 	15.3	  	Severability	  	 	37	  
				
		 	15.4	  	Governing Law; Dispute Resolution	  	 	37	  
				
		 	15.5	  	Notices	  	 	38	  
				
		 	15.6	  	Entire Agreement; Modifications	  	 	39	  
				
		 	15.7	  	Relationship of the Parties	  	 	39	  
				
		 	15.8	  	Waiver	  	 	39	  
				
		 	15.9	  	Counterparts	  	 	39	  
				
		 	15.10	  	No Benefit to Third Parties	  	 	40	  
				
		 	15.11	  	Further Assurance	  	 	40	  
				
		 	15.12	  	No Drafting Party	  	 	40	  
				
		 	15.13	  	Construction	  	 	40	  
				
		 	15.14	  	Assignment to Horizon	  	 	40	  
				
		 	15.15	  	Amendment and Restatement; No Novation	  	 	41	  
		
	 SCHEDULES
	  			
		
	Schedule 1.43 – Licensed Patents	  			
		
	Schedule 1.83 - Vimovo Trademarks	  			
		
	Schedule 8.1.3 – Market Reduction Example	  			

  
 -iv- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH
HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT 

FOR THE UNITED STATES 

THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and
entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina
(“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a
“Party,” or collectively as the “Parties.” 
 RECITALS 

A. WHEREAS, POZEN and Licensee are parties to that certain Collaboration and License Agreement, dated as of August 1, 2006 and as
amended as of September 6, 2007, October 1, 2008 and September 16, 2013 (as amended, the “Original Agreement”); 

B. WHEREAS, Licensee is in discussions with Horizon Pharma USA, Inc. (“Horizon”) to divest Licensee’s (and its
Affiliates’) rights to Products (as defined below) in the United States (such transaction, the “Divestiture”); and 

C. WHEREAS, to facilitate the proposed Divestiture, Licensee and POZEN desire to amend and restate the terms of the Original Agreement
in two separate agreements: (a) this Agreement, which contains the terms and conditions pursuant to which Licensee (or its assignee) will have a license to POZEN’s intellectual property to manufacture, develop and commercialize the
Products (as defined below) in the United States, which will be assigned to Horizon in connection with the Divestiture, and (b) another agreement that contains the terms and conditions pursuant to which Licensee (or its designee) will have a
license to POZEN’s intellectual property to manufacture, develop and commercialize the Products throughout the world outside of the United States and Japan (the “ROW Agreement”). 

In consideration of the foregoing premises, the mutual promises and covenants set forth in this Agreement, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, POZEN and Licensee hereby agree as follows: 
 AGREEMENT

  

	1.	DEFINITIONS 

 When used in this Agreement, capitalized terms will have the meanings as
defined below and throughout the Agreement. All financial and accounting terms not otherwise defined in this Agreement, whether capitalized or not, shall have the meanings assigned to them in accordance with generally accepted accounting principles
based on International Accounting Standards/International Financial Reporting Standards as in effect from time to time (“IFRS”). 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.1 “Adverse Event” means any adverse medical occurrence in a patient or
clinical investigation subject that is administered a pharmaceutical product, as designated under 21 CFR § 312.32 and any other Applicable Law in the Territory. 

1.2 “Affiliate” means a legal entity that, directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with an entity. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means (a) the
possession, directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided, that if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum
ownership percentage that may, under such local law, be owned by foreign interests. 
 1.3 “Amended and Restated Effective
Date” has the meaning set forth in Section 12.1. 
 1.4 “Amended and Restated Execution Date” has the meaning set
forth in the preamble. 
 1.5 “Applicable Law” means the laws, rules, and regulations, including any statutes, rules,
regulations, guidelines, or other requirements that may be in effect from time to time and apply to the activities contemplated by this Agreement in the Territory. 

1.6 “Blocking Patent” means a Patent owned or controlled by a Third Party, one or more Valid Claims of which, in the absence
of a license thereunder, would be infringed by the making, use, sale, offering for sale, or importation of a POZEN Product in the Territory. 

1.7 “Business Combination” means any merger, consolidation, sale of stock, sale or transfer of all or substantially all of
the assets, or other similar transaction to which POZEN is a party, other than (i) any merger, consolidation, or similar transaction following which the individuals and entities who were the beneficial owners of the outstanding voting
securities of POZEN immediately prior to such transaction still beneficially own, directly or indirectly, more than fifty percent (50%) of the voting power of the surviving entity immediately after such transaction; or (ii) any merger,
consolidation, sale of stock, sale or transfer of all or substantially all of the assets, or other similar transaction permitted under Section 15.1 (Assignment). 

1.8 “Business Day” means any day other than (i) Saturday or Sunday or (ii) any other day on which banks in New
York, New York, United States, the United Kingdom or Sweden are permitted or required to be closed. 
 1.9 “Calendar
Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

  
 -2- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.10 “cGCP” means current good clinical practices as defined in U.S.
Regulations 21 CFR §§ 50, 54, 56, 312 and 314, (or in the case of foreign jurisdictions, comparable regulatory standards), the International Conference of Harmonization (ICH) E6 “Good Clinical Practice: Consolidated Guidance,”
and in any successor regulation or any official guidance documents issued by an applicable Regulatory Authority. 
 1.11
“cGLP” means current good laboratory practice standards as defined by the FDA pursuant to 21 CFR Part 58 (or in the case of foreign jurisdictions, comparable regulatory standards), and in any successor regulation or any official
guidance documents issued by a Regulatory Authority. 
 1.12 “cGMP” means current good manufacturing practices as contained
in 21 CFR Parts 210 and 211 as amended from time to time and any equivalents contained in regulations in countries outside the U.S. 

1.13 “Change of Corporate Control” means the occurrence of either of the following: 

(a) a Business Combination involving POZEN; or 

(b) the acquisition (whether in a single transaction or series of related transactions) after the Effective Date by a Third Party or
Group of beneficial ownership of *** *** (***%) *** of POZEN’s voting securities. 
 1.14 “Combination Product” means
a Product that includes one or more pharmaceutically active ingredients (in addition to a single Gastroprotective Agent and a single NSAID) and is sold in final form either in a single fixed combination oral solid dosage or as separate doses in a
single package and priced as one item. 
 1.15 “Commercial Launch” means the nationwide commercial sale, promotion and
distribution of POZEN Product in the Territory following receipt of Marketing Approval in the Territory. 
 1.16
“Commercialization” means all activities relating to the manufacture, marketing, promotion, advertising, selling and distribution of Product in the Territory, including pre-Commercial Launch market development activities conducted in
anticipation of Marketing Approval of Product, including, without limitation, seeking pricing and reimbursement approvals for Product, preparing advertising and promotional materials, sales force training, and all interactions and activities
(e.g., dossier preparations and filings) associated with Regulatory Authorities regarding the commercialization of Product and the maintenance of Marketing Approvals. The term “Commercialize” has a correlative meaning. 

1.17 “Commercialized POZEN Product” has the meaning set forth in Section 12.8 (Formulation Technology). 

1.18 “Competing Product” means, with respect to a particular Product being Commercialized by Licensee or any of its
Affiliates or Sublicensees in the Territory, a product being marketed by or on behalf of a Third Party (other than a Sublicensee) in the Territory containing at least *** that are *** those in the *** and are ******. 

  
 -3- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.19 “Controlled” means, with respect to any Know-How, Patent, or other
intellectual property right, the possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or under, such Know-How, Patent or right as
provided for herein without violating the terms of any agreement or other arrangements with any Third Party. 
 1.20 “Develop”
or “Development” means all activities relating to pre-clinical and clinical development of a Product and all development activities relating to the preparation and filing of NDAs and obtaining of Marketing Approvals, price and
reimbursement approvals in the Territory, including, without limitation, preparing and conducting pre-clinical testing, toxicology testing, human clinical studies, regulatory affairs. 

1.21 “Diligent Efforts” means, with respect to the Development, Manufacture or Commercialization by Licensee of a product, at
any given time as the case may be, efforts and resources reasonably used by Licensee or its Affiliates (giving due consideration to relevant industry standards) for Licensee’s own products (including internally developed, acquired and
in-licensed products) with similar commercial potential at a similar stage in their lifecycle (assuming continuing development of such product), taking into consideration their safety, tolerability and efficacy, the profitability (taking into
account any payments payable under this Agreement or the Three-Party Agreement), the extent of market exclusivity, patent protection, cost to develop the product, promotable claims, and health economic claims. 

1.22 “Divestiture” has the meaning set forth in the recitals. 

1.23 “Duexis” means the pharmaceutical product containing ibuprofen and famotidine in a single fixed combination dosage form,
which product is being commercialized as of the Amended and Restated Effective Date by Horizon or its Affiliates in the Territory as Duexis®. 

1.24 “Effective Date” means the date on which the Original Agreement became effective pursuant to the terms thereof. 

1.25 “Esomeprazole” means that certain pharmaceutical compound with the name
(5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole), including any ***. 
 1.26 “Execution
Date” means August 1, 2006. 
 1.27 “FDA” means the United States Food and Drug Administration, or any
successor agency thereto. 
 1.28 “Field of Use” means the treatment of human diseases and conditions by means of a
pharmaceutical product. 
 1.29 “First Commercial Sale” means, with respect to a Product, the date on which Licensee or its
Affiliate or Sublicensee first sells the Product intended for commercial distribution to any Third Party after receipt of NDA Approval of such Product in the Territory (including, without limitation, sale in an individual state or similar
sub-national political 

  
 -4- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
subdivision in which Marketing Approval may be received); provided, that with respect to the Initial Pozen Product, “First Commercial Sale” means July 6, 2010. Sale of a
Product for clinical studies, compassionate use, named patient programs, under a treatment IND, test marketing, any clinical studies, or any similar instance where the Product is supplied with or without charge will not constitute a First Commercial
Sale. 
 1.30 “Formulation Technology” means any Know-How Controlled by Licensee in the Licensee Inventions that are used
by Licensee in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or
Know-How to the extent directed to a Gastroprotective Agent, non-steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof. 

1.31 “Gastroprotective Agent” means proton pump inhibitors and H2 receptor antagonists for the treatment, prevention or
amelioration of injury to the gastrointestinal tract. 
 1.32 “Group” means a group of related persons or entities deemed a
“person” for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. 
 1.33 “Horizon”
has the meaning set forth in the recitals. 
 1.34 “IND” means an Investigational New Drug Application filed with the FDA
pursuant to 21 CFR § 312.20. 
 1.35 “Indirect Tax” means value added taxes, sales taxes, consumption taxes and
other similar taxes. 
 1.36 “Initial POZEN Product” means the POZEN Product containing non-enteric coated Esomeprazole and
enteric-coated Naproxen that is the subject of NDA #22-511. 
 1.37 “Invention” means any invention, discovery or Know-How
that is conceived during the Term in the performance of activities undertaken pursuant to this Agreement by employees, agents, or independent contractors of either Party, its Affiliates or Sublicensees and is Controlled by such Party, Affiliates or
Sublicensees. 
 1.38 “Joint Invention” means any Invention that is conceived jointly by one or more employees, agents, or
independent contractors of Licensee or its Affiliate(s) and one or more employees, agents, or independent contractors of POZEN or its Affiliate(s). 

1.39 “Joint Patent” means a Patent claiming a Joint Invention. 

1.40 “JSC” has the meaning set forth in Section 2.1.2 (Joint Steering Committee). 

1.41 “Know-How” means any non-public, documented or otherwise recorded or memorialized knowledge, experience, know-how,
technology, information, and data, including formulas and formulations, processes, techniques, unpatented inventions, discoveries, ideas, and developments, test procedures, and results, together with all documents and files embodying the foregoing.

  
 -5- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.42 “Licensed Know-How” means any Know-How that is necessary or useful for
the Development, Manufacture or Commercialization of Product in the Field of Use in the Territory and that is Controlled by POZEN or any of its Affiliates as of the Effective Date or during the Term. 

1.43 “Licensed Patents” means: (a) the Patents set forth on Schedule 1.43, and any substitutions, divisions,
continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, or extensions of such Patents, (b) any Patents in the Territory Controlled by POZEN or any of its Affiliates as of the Effective Date or
during the Term that claim Inventions (including without limitation POZEN’s interest in Joint Inventions), and (c) all other Patents in the Territory Controlled by POZEN or any of its Affiliates as of the Effective Date or during the Term
that are necessary or useful for the Development, Manufacture or Commercialization of a Product in the Territory. Notwithstanding anything in this Section 1.43 to the contrary, Licensed Patents shall not include any Patents Controlled by POZEN
with Valid Claims that do not cover any Product (e.g., any Patents with Valid Claims solely directed to any product containing acetyl salicylic acid). 

1.44 “Licensed Technology” means the Licensed Patents and the Licensed Know-How. 

1.45 “Licensee House Marks” means any trademarks, trade names, domain names, or other names or marks used or registered by
Licensee or its Affiliates at any time during the Term to identify itself. 
 1.46 “Licensee Invention” means any Invention
that is conceived solely by one or more employees, agents, or independent contractors of Licensee or its Affiliate(s). 
 1.47
“Manufacture” means all activities related to the manufacturing of a Product, or any ingredient thereof, in the Territory, including but not limited to formulation development and process development for the manufacture of a Product,
manufacturing supplies for Development, manufacturing for commercial sale, packaging, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and
release of product, ongoing stability tests and regulatory activities related to any of the foregoing. “Manufacture” shall not include any of the above activities with respect to Esomeprazole as an active ingredient. 

1.48 “Market Reduction” has the meaning set forth in Section 8.1.3 (Rate Step Down for Competing Product Entrants). 

1.49 “Marketing Approval” means all approvals (including NDA Approvals and, where available under Applicable Law, pricing and
reimbursement approvals in accordance with Applicable Law) of any Regulatory Authority in the Territory, that are necessary or useful to be obtained prior to the manufacture or Commercialization of a Product in the Territory. For purposes of
clarification, “Marketing Approval” in the U.S. shall have the same meaning as NDA Approval in the U.S. 

  
 -6- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.50 “Naproxen” means that certain pharmaceutical compound with the chemical
name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneacetic acid, including any ***. 
 1.51 “NDA” means a New Drug Application
filed with the FDA as described in 21 CFR § 314. 
 1.52 “NDA Approval” means receipt of a letter from the FDA
approving an NDA. 
 1.53 “Net Sales” means with respect to any Product, the gross amounts recognized by Licensee, its
Sublicensees or its Affiliates from Third Party customers for sales of a Product in the Territory, less the following deductions made by Licensee (to the extent not already taken by Licensee in the Product invoice or in amounts recognized), its
Sublicensees or its Affiliates in arriving at net sales as reported in the Licensee statutory accounts prepared in accordance with IFRS: 

(a) actual credited allowances to such Third Party customers for spoiled, damaged, rejected, recalled, outdated and returned Product
and for retroactive price reductions; 
 (b) the amounts of trade and cash discounts actually granted to Third Party customers, to
the extent such trade and cash discounts are specifically allowed on account of the purchase of such Product; 
 (c) sales taxes,
excise taxes and import/export duties actually due or incurred in connection with the sales of a Product to any Third Party customer; 

(d) allowances, adjustments, reimbursements, discounts, chargebacks and rebates actually granted to Third Party customers (not in
excess of the selling price per unit of such Product); 
 (e) other deductions from gross sales made in arriving at net sales as
reported in the Licensee statutory accounts; and 
 (f) allowance for transportation costs, distribution expenses, special packaging
and related insurance charges in the amount of *** (***) of the Net Sales calculated after applying the deductions of items (a)-(e) above. 
 Net Sales
shall be calculated using Licensee’s internal audited systems used to report such sales as adjusted for any of items (a)-(f) above not taken into account in such systems. Notwithstanding the
foregoing, if Product is sold as a Combination Product, the Net Sales used for the calculation of the royalties under Section 8.1 (Royalties) shall be determined as follows: 

 

					
	A	  	×	  	Net Sales of the Combination Product, where:
	A+B	  	  
		
	  A =	  	Standard Sales Price of the ready-for-sale form of the Product if sold separately from the Combination Product in question, in the Territory.

  
 -7- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

			
	B =	  	Standard Sales Price of the ready-for-sale form of a product containing the same amount of the other therapeutically active ingredient(s) that is contained in the Combination Product in question, in the Territory.

 If (a) the other therapeutically active ingredient(s) in such Combination Product are not sold separately in the
Territory, Net Sales shall be adjusted by multiplying actual Net Sales of such Combination Product by the fraction A/C, where C is the Standard Sales Price in the Territory of such Combination Product, and (b) if a Product contained in the
Combination Product is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-B)/C, where B is the Standard Sales Price in the Territory of the other therapeutically active
ingredient(s) in the Combination Product and C is the Standard Sales Price in the Territory of the Combination Product. If both a Product in a Combination Product and a product containing the other active ingredients in such Combination Product are
not sold separately, a market price for such Product and such other active ingredients shall be negotiated by the Parties in good faith based upon the market price of products that are comparable to such Product or such other active ingredients, as
applicable. If the Product in the Combination Product is marketed in the Territory, the Standard Sales Price of the Product in such Combination Product for purposes of calculating the royalty payable to POZEN will be no less than *** *** (***) of
the Standard Sales Price of the Product sold outside of such Combination Product in the Territory. 
 In addition, and notwithstanding the foregoing, if a
Product is sold together with other goods with or without a separate price for such Product (such group of products including the Product a “Product Set”), then the Net Sales applicable to the quantity of such Product included in
any such transaction will be calculated as follows: 
  

					
	A	  	×	  	Net Sales of the Product Set, where:
	A+B	  	  
		
	  A =	  	Standard Sales Price of the Product if sold separately from the Product set in question, in the Territory.
		
	  B =	  	The total of the Standard Sales Prices of all products in the Product Set other than the Product, in the Territory.

 1.54 “Nexium” means AstraZeneca AB’s and its Affiliates’ products containing
Esomeprazole as the sole active ingredient in any presentation form. 
 1.55 “Nexium Business” means AstraZeneca AB’s
and its Affiliates’ development and commercialization activities pertaining to Esomeprazole and Esomeprazole based products. 
 1.56
“NSAID” means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of cyclooxygenase, but excluding acetyl salicylic acid (including salts and derivatives thereof). 

  
 -8- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.57 “Original Agreement” has the meaning set forth in the recitals. 

1.58 “Patent Challenge” has the meaning set forth in Section 9.9. 

1.59 “Patents” means (a) all patents and patent applications in any country or supranational jurisdiction, and
(b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any
such patents or patent applications. 
 1.60 “Post-Approval Failure” means: (a) a mandatory withdrawal or recall of a
Product by a Regulatory Authority, or (b) any voluntary withdrawal or recall of a Product that arises from risks associated with a serious adverse health consequence or death reported to a Regulatory Authority anywhere in the world.
Notwithstanding the foregoing, any such recall that results primarily from Licensee’s or its Affiliate’s or Sublicensee’s gross negligence, willful misconduct, or failure to comply with Applicable Law in the Development, Manufacture
or Commercialization of a Product in the Territory shall not be considered a Post-Approval Failure for purposes of this Agreement. 

1.61 “POZEN House Marks” means any trademarks, trade names, domain names, or other names or marks used or registered by POZEN
or its Affiliates at any time during the Term to identify itself. 
 1.62 “POZEN Invention” means any Invention that is
conceived solely by one or more employees, agents, or independent contractors of POZEN or its Affiliate(s). 
 1.63 “POZEN
Product” means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported in the Territory without a license
from POZEN of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents. 
 1.64 “Product” means:
(a) any POZEN Product, and (b) any other product that combines a Gastroprotective Agent and any NSAID in a single fixed combination oral solid dosage form (with or without one or more additional therapeutically active agents), which
product is developed or commercialized by or for, invented or acquired by, or comes under the Control of Licensee or its Affiliates during the Term, but in each case excluding Duexis. For the avoidance of doubt, “Product” does not include
any product containing acetyl salicylic acid (including salts and derivatives thereof). 
 1.65 “Product Labeling” means
(a) the full prescribing information for a POZEN Product approved by the applicable Regulatory Authority in the Territory, and (b) all labels and other written, printed or graphic information included in or placed upon any container,
wrapper or package insert used with or for the POZEN Product in the Territory. 

  
 -9- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.66 “Product Trademarks” means (a) the VIMOVO Trademarks and
(b) any other trademarks, trade dress (including packaging design), logos, slogans, domain names and designs, whether or not registered in a country or territory, selected by Licensee and used to identify or promote a POZEN Product, but
excluding any POZEN House Marks and Licensee House Marks. 
 1.67 “Promotional Materials” means all sales representative
training materials and all written, printed, graphic, electronic, audio or video presentations of information, including, without limitation, journal advertisements, sales visual aids, formulary binders, reprints, direct mail, direct-to-consumer
advertising, internet postings, broadcast advertisements and sales reminder aides (for example, note pads, pens and other such items) intended for use or used by Licensee or its Affiliates in connection with any promotion of the Initial POZEN
Product hereunder in the Territory, but excluding Product Labeling. 
 1.68 “PT” means Licensee’s product team
operating pursuant to Licensee’s instructions for product teams for the Initial POZEN Product in the Territory with representatives of Licensee having expertise in the areas of research & development, marketing, regulatory,
intellectual property, finance, toxicology, and other areas. 
 1.69 “PT Chair” will have the meaning set forth in
Section 2.2.1 (PT). 
 1.70 “Regulatory Authority” means, in a particular country or jurisdiction, any applicable
government regulatory authorities involved in granting approval to market or sell a Product, including any pricing and reimbursement approvals, in such country or jurisdiction, including, (a) in the United States, the FDA, and any successor
government authority having substantially the same function, (b) any non-United States equivalent thereof, and (c) in the EU, the European Medicines Agency, or any successor agency thereto, and any national regulatory authority in any EU
country. 
 1.71 “Regulatory Materials” means regulatory applications, submissions, notifications, registrations, Marketing
Approvals or other submissions made to or with a Regulatory Authority that are necessary or reasonably desirable in order to develop, manufacture, market, sell or otherwise Commercialize the Initial POZEN Product in the Territory. Regulatory
Materials include, without limitation, INDs and NDAs, and amendments and supplements for any of the foregoing, and applications for pricing and reimbursement approvals. 

1.72 “ROW Agreement” has the meaning set forth in the recitals. 

1.73 “ROW Party” has the meaning set forth in Section 7.4(b). 

1.74 “Royalty Term” has the meaning set forth in Section 8.1.2 (Royalty Term). 

1.75 “Standard Sales Price” means, as reported by IMS (or ACNielsen in the case of over-the-counter products) in the
Territory, the average sales price for the preceding Calendar Quarter for the Product or, in the case of a Combination Product, the average sales price for the applicable presentation and dosage strength of all marketed brands of the other
therapeutically active ingredient(s). As used herein, “presentation” means the method of administration of a pharmaceutical substance into the human body, including, but not limited to, solid oral (including tablets, capsules, gelcaps,
sachets and caplets), other oral (including suspension and solution), parenteral (including intramuscular, subcutaneous and intravenous), transdermal, suppository and intranasal. 

  
 -10- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 1.76 “Sublicense Agreement” means any agreement under which Licensee grants
a Third Party a sublicense, option or other right under the Licensed Technology to make, use, have made, sell, offer for sale, import and export Products in the Field of Use in the Territory. 

1.77 “Sublicensee” means any Third Party that has entered into a Sublicense Agreement. 

1.78 “Term” has the meaning assigned to it in Section 12.2 (Term). 

1.79 “Territory” means the United States. 

1.80 “Third Party” means any entity other than POZEN, Licensee, or any of their respective Affiliates. 

1.81 “Third Party Royalties” means upfront, commercialization milestone, royalty and any other similar payments paid by
Licensee or any Licensee Affiliate or Sublicensee to any Third Party in consideration for a license to a Blocking Patent for the Development or Commercialization of POZEN Products in the Territory. 

1.82 “Three-Party Agreement” means that certain letter agreement of even date herewith by and among
AstraZeneca AB, POZEN and Horizon. 
 1.83 “Vimovo Trademarks” means the trademark VIMOVO and the
other trademarks and logos listed on Schedule 1.83 and any variations thereof. 
 1.84 “U.S.” or “United States”
means the United States of America and its possessions and territories. 
 1.85 “Valid Claim” means any claim of any issued
and unexpired patent or a patent application that has not been disclaimed or held invalid or unenforceable by judgment or decree entered in any judicial proceeding that is not further reviewable through the exhaustion of all permissible applications
for rehearing or review by a superior tribunal, or through the expiration of the time permitted for such applications; provided, that any claim in a pending Patent application that does not issue as a patent claim within *** (***) years after the
earliest priority date of such application will not be a “Valid Claim” until such claim issues as a patent claim. 
  

	2.	COLLABORATION GOVERNANCE 

 2.1 Establishment. 

2.1.1 Product Team. Within twenty (20) days after the Amended and Restated Effective Date, the Parties will appoint representatives
to the PT in accordance with the terms of this Section 2.1 and convene the first PT meeting. The PT will coordinate and oversee the Commercialization of the Initial POZEN Product hereunder. The purposes of the PT will be, with respect to the
Initial POZEN Product only, to develop Licensee’s marketing plans for the Initial POZEN Product in the Territory. The PT will have the membership and will operate by the procedures set forth in Section 2.2 (Membership and Procedures). 

  
 -11- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 2.1.2 Joint Steering Committee Promptly following the Amended and Restated Effective
Date, the Parties will create a joint steering committee (the “JSC”) to provide strategic guidance to the PT in decisions pertaining to the Initial POZEN Product in the Territory. The purposes of the JSC will be to resolve disputes
of the PT. The JSC will have the membership and will operate by the procedures set forth in Section 2.2 (Membership and Procedures). 

2.2 Membership and Procedures. 

2.2.1 PT. 
 (a)
Membership. In addition to members designated by Licensee, the PT shall have up to three (3) representatives designated by POZEN, attending, observing and participating in meetings of the PT at POZEN’s expense, such representatives
having the relevant experience and skill appropriate for service on such team. Attendance of POZEN representatives at PT meetings shall be agenda-driven, as determined in the sole discretion of Licensee. Licensee shall be entitled to have as many
representatives serve as members of the PT as it desires. POZEN may replace its representatives on the PT at any time upon written notice to Licensee. Licensee shall provide POZEN with office space at its facilities for such representatives to
facilitate such participation; provided, that such representatives shall comply with all policies and reasonable restrictions imposed by Licensee and provided to POZEN in writing. Upon prior written consent of Licensee, which consent will not be
unreasonably withheld, a reasonable number of employees, consultants, representatives or advisors of POZEN who are not POZEN’s PT representatives may attend PT meetings as observers; provided, that such persons shall comply with all policies
and reasonable restrictions imposed by Licensee and provided to POZEN in writing. 
 (b) Chairpersons. The product director
designated by Licensee for the Initial POZEN Product will chair the PT (“PT Chair”). 
 (c) Meetings. The PT will
hold meetings when called by the PT Chair. Meetings may be held in person or by means of telecommunication (telephone, video, or web conference). Face-to-face PT meetings that require POZEN attendance will be convened on an as-needed basis as
mutually agreed by Licensee and POZEN, but in any event, at least twice per annum. The location of these meetings, will be based on business requirements and determined by mutual agreement between Licensee and POZEN. Following any PT meeting, the PT
Chair will be responsible for preparing and issuing minutes of such meeting within fifteen (15) Business Days thereafter. When POZEN has participated in the meeting, such minutes will not be finalized until a representative of the PT designated
by each Party has reviewed and confirmed the accuracy of such minutes in writing. If a disagreement regarding the accuracy of such minutes cannot be resolved, the minutes will reflect such disagreement. 

  
 -12- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 2.2.2 JSC. 

(a) Membership. Each Party will designate an equal number of representatives, but in no event less than three (3) each, with
appropriate expertise to serve as members of the JSC. Each Party may replace its representatives on the JSC at any time upon written notice to the other Party. 

(b) Co-Chairpersons. One of each Party’s representatives to the JSC will be designated as a co-chairperson. The co-chairpersons
will be responsible for calling meetings and preparing and circulating an agenda in advance of each meeting, and preparing minutes of each meeting. 

(c) Meetings. The JSC will hold meetings at least once every Calendar Quarter, or more frequently as the Parties may agree with at
least two meetings held in person annually. Subject to the preceding sentence, meetings may be held in person at locations to be determined by the mutual agreement of the Parties or by means of telecommunication (telephone, video, or web
conferences). Following any JSC meeting, the co-chairpersons will be responsible for preparing and issuing minutes of such meeting within fifteen (15) Business Days thereafter. Such minutes will not be finalized until a representative of each
Party has reviewed and confirmed the accuracy of such minutes in writing. If a disagreement regarding the accuracy of such minutes cannot be resolved, the minutes will reflect such disagreement. 

2.2.3 Limitations of Powers. The PT and JSC will have only such powers as are specifically delegated to them hereunder and will not be
a substitute for the rights of the Parties. Without limiting the generality of the foregoing, the PT and JSC will not have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement may only be implemented
pursuant to Section 15.6 (Entire Agreement; Modifications) below. 
 2.2.4 Expenses. Each Party will be responsible for all of its
own expenses of participating in the PT and JSC. 
 2.3 Decision-Making. 

2.3.1 PT Decisions. Subject to the terms of this Section 2.3 (Decision-Making), the PT will act by decision of the PT Chair. If a
POZEN representative objects to any decision, then such dispute will be referred to the JSC. 
 2.3.2 JSC Decisions. Subject to the
terms of this Section 2.3 (Decision-Making), the JSC will take action by unanimous vote with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by a written resolution signed
by the designated representatives of each of the Parties. If the JSC fails to reach unanimous consent on a particular matter within *** (***) Business Days of POZEN having requested a formal vote on such matter (or any earlier period mutually agreed
to by the Parties if a delay may reasonably be anticipated to have an adverse effect on the Commercialization of the Initial POZEN Product in the Territory), then such dispute will be subject to the resolution procedures described in
Section 2.3.3 (Dispute Resolution) below. 

  
 -13- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 2.3.3 Dispute Resolution. In the event of any dispute in the JSC that is not resolved
pursuant to the terms of Section 2.3.2 (JSC Decisions), either Party may provide written notice of such failure (a “Notice of Disagreement”) to the Chief Executive Officer of the other Party (or his or her designee). The Chief
Executive Officers or designees of each of the Parties will meet at least once in person or by means of live telecommunication (telephone, video, or web conferences) to discuss the matter on which the JSC failed to reach unanimous consent and use
their good faith efforts to resolve the matter within *** (***) Business Days after receipt of the Notice of Disagreement by the applicable Chief Executive Officer of a Party. If any such disagreement is not resolved by the Chief Executive Officers
or designees within such *** (***) Business Day period, then the Chief Executive Officer or designee of Licensee will have the final decision-making authority with respect to disagreement relating to any and all matters. 

2.3.4 Limitation. Notwithstanding this Section 2.3 (Decision-Making), any dispute regarding the interpretation of this Agreement,
the performance or alleged nonperformance of a Party’s obligations under this Agreement, or any alleged breach of this Agreement will be resolved in accordance with the terms of Section 15.4 (Governing Law; Dispute Resolution). 

2.4 Operating Principles. Promptly after the Amended and Restated Effective Date, the Parties will agree in writing on operating
principles to guide the conduct of the PT and JSC. To the extent there is any conflict between such operating principles and the terms and conditions of the Agreement, then the Agreement will control. 

 

	3.	[INTENTIONALLY OMITTED] 

  

	4.	REGULATORY MATTERS 

 4.1 Responsibilities. Licensee shall have the
sole right at its own expense to (a) seek any Marketing Approval for Products in the Territory, including Marketing Approval for claims not obtained in the initial NDA Approval for the Initial POZEN Product, and (b) prepare or make any
filings or submissions to, or otherwise communicate with, any Regulatory Authority in the Territory regarding Products. For clarity, Licensee shall own all Marketing Approvals and Regulatory Materials pertaining to Products in the Territory. Without
limiting the foregoing, as owner of the NDA Approval for the Initial POZEN Product, Licensee will be the sole owner of all data exclusivity protection related to the Initial POZEN Product in the Territory as provided by Applicable Law. 

4.2 Access to Filings. Licensee and its Affiliates will have the right of cross-reference to all NDAs or other filings made by or on
behalf of POZEN for the purpose of prosecuting Marketing Approval applications for Products in the Territory, and POZEN and its Affiliates will, or will use reasonable efforts to cause their licensees to, take all such reasonable actions to allow
such cross-reference. 
 4.3 Interactions with Regulatory Authorities. 

4.3.1 Consultation. Each Party will consult with the other Party regarding (and provide copies of materials prior to any submission to a
Regulatory Authority and materials after receipt from a Regulatory Authority), and keep such other Party reasonably and regularly informed of, the status of the preparation of all Regulatory Materials in the Territory, review of such materials by
the relevant Regulatory Authority in the Territory, and Marketing Approvals received for the Initial POZEN Product in the Territory. 

  
 -14- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 4.3.2 Communications. Except as may be required by Applicable Law, only Licensee will
communicate regarding POZEN Products, including the Initial POZEN Product, with any Regulatory Authority in the Territory. If POZEN is required to make such a communication by a Regulatory Authority, then POZEN will ***. 

4.4 Exchange of Know-How; Information Sharing. As of the Amended and Restated Effective Date, each Party has provided to the other
Party copies of all Know-How in its possession relating to the Initial POZEN Product, including, without limitation, procedures, formulations, manufacturing reports, pre-clinical and clinical protocols and data, regulatory filings, and toxicology
reports with respect to the Initial POZEN Product, including any final versions of any study reports and any drafts outstanding of any study reports, all to the extent reasonably required for a Party to perform its obligations under this Agreement.
Each Party will provide to the other Party copies of any Know-How that comes into its possession on or after the Amended and Restated Effective relating to the Initial POZEN Product, including, without limitation, procedures, formulations,
manufacturing reports, pre-clinical and clinical protocols and data, regulatory filings, and toxicology reports with respect to the Initial POZEN Product, including any final versions of any study reports and any drafts then-outstanding of any study
reports, all to the extent reasonably required for a Party to perform its obligations under this Agreement. In addition, each Party will provide the other Party, in a timely manner, with copies of, and all information received by it pertaining to,
notices, questions, actions and requests from or by Regulatory Authorities with respect to the Initial POZEN Product in the Territory, or the testing, Manufacture, packaging, distribution or facilities in relation thereto, including any notices of
non-compliance with laws in connection with the Initial POZEN Product (e.g., warning letters or other notices of alleged non-compliance), audit notices, notices of initiation by Regulatory Authorities of investigations, inspections,
detentions, seizures or injunctions concerning the Initial POZEN Product (or its manufacture, distribution, or facilities connected thereto), notice of violation letters (i.e., an untitled letter), warning letters, service of process or other
inquiries. Except as otherwise set forth in this Agreement or to comply with Applicable Law, ***. 
 4.5 Regulatory Audits. If a
Regulatory Authority in the Territory desires to conduct an inspection or audit of a Party’s facility, or a facility under contract with a Party, with regard to a POZEN Product, then such Party will promptly notify the other Party and permit
and cooperate with such inspection or audit, and will cause the contract facility to permit and cooperate with such Regulatory Authority and such other Party during such inspection or audit. Licensee will have the right upon request (which request
shall not be unreasonably withheld) to have a representative observe such inspection or audit with respect to a POZEN facility, or a facility under contract with POZEN. Following receipt of the inspection or audit observations of such Regulatory
Authority (a copy of which the audited Party will immediately provide to the other Party), the audited Party will prepare the response to any such observations, and will provide a copy of such response to the other Party. The audited Party agrees to
conform its activities under this Agreement to any commitments made in such a response, except to the extent it believes in good faith that such commitments violate Applicable Laws. 

  
 -15- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 4.6 Adverse Event Reporting. 

4.6.1 Licensee will maintain and will be the recognized holder of the safety database for AE and SAE reports related to POZEN Products
in the Territory. Direct access to this database will not be granted to POZEN. Upon request, all reasonable assistance will be provided by either Party in responding to safety inquiries in the Territory. 

4.6.2 Each Party shall keep the other Party informed of notification of any action by, or notification or other information which it
receives (directly or indirectly) from any Regulatory Authority in the Territory which: (i) raises any material concerns regarding the safety or efficacy of the Initial POZEN Product; (ii) indicates or suggests a potential material
liability for either Party to Third Parties arising in connection with the Initial POZEN Product; (iii) is reasonably likely to lead to a “Dear Doctor” letter, recall or market withdrawal of the Initial POZEN Product;
(iv) relates to the Initial POZEN Product, Regulatory Materials, Promotional Materials, samples, package inserts, the indications, labeling, expedited and periodic Adverse Event Reports, medical inquiries, Initial POZEN Product complaints, this
Agreement, or (v) is otherwise important to the Development and/or Commercialization of the Initial POZEN Product. 
 4.7 Records
and Reports. Each Party will retain all records required by Applicable Law to be maintained in connection with such Party’s performance of Development activities under this Agreement. 

 

	5.	DEVELOPMENT AND COMMERCIALIZATION 

 5.1 Development and Commercialization. As
between the Parties, Licensee will be solely responsible for the Development and Commercialization of POZEN Products in the Territory during the Term. 

5.2 Regulatory Obligations. Licensee will own and maintain all regulatory filings and Marketing Approvals in the Territory for POZEN
Products, including all INDs and NDAs for the Initial POZEN Product. As between the Parties, but subject to ***, Licensee will be solely responsible for all activities in connection with maintaining Marketing Approvals required for the
Commercialization and manufacture of POZEN Products in the Territory, including communicating and preparing and filing all reports (including Adverse Event reports) with the applicable Regulatory Authorities in the Territory. 

5.3 Performance; Diligence. Licensee will use Diligent Efforts to Commercialize a POZEN Product in the Territory. The foregoing
Diligent Efforts requirement will apply only to one POZEN Product in the Territory, irrespective of the number of POZEN Products Licensee elects to Develop and Commercialize, and Licensee may elect to fulfill its Diligent Efforts obligation in the
Territory in respect to any POZEN Product of its choice in the exercise of its reasonable and good faith judgment. Licensee will have the right to Develop and Commercialize Products during the Term in the Territory, for so long as Licensee is using
Diligent Efforts to Commercialize at least one POZEN Product in accordance with this Section 5.3, it being understood that the Parties intend for Licensee to focus its initial efforts on the Commercialization of the Initial POZEN Product in the
Territory. 

  
 -16- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 5.4 Threatened Removal. In the event that any governmental authority threatens or
initiates any action to remove any POZEN Product from the market in the Territory, Licensee will promptly notify POZEN of such communication. Any voluntary recall or withdrawal of any POZEN Product in the Territory will be at Licensee’s sole
discretion and expense. Before Licensee initiates a recall or withdrawal in the Territory, the Parties will promptly and in good faith discuss the reasons therefor; provided, that such discussions do not delay the recall or withdrawal. In the event
of any recall or withdrawal of any POZEN Product in the Territory, Licensee will implement any necessary action, with assistance from POZEN as reasonably requested by Licensee. 

5.5 Compliance. Each Party will comply with all Applicable Laws relating to activities performed or to be performed by such Party (or
its Affiliates or contractors) under or in relation to the Commercialization of the Initial POZEN Product in the Territory pursuant to this Agreement. Each Party represents, warrants and covenants to the other Party that as of the Effective Date and
during the Term, such Party and its Affiliates have adequate policies and procedures in place: (i) to ensure their compliance with such laws; (ii) to bring any non-compliance therewith by any of the foregoing entities to its attention; and
(iii) to promptly remedy any such non-compliance. 
 5.6 Branding; Trademarks; Domain Names; Trade Dress; Logos. 

5.6.1 Responsibilities. As between the Parties, Licensee will select all Product Trademarks for use on or in connection with POZEN
Products in the Territory, will be the sole owner of the Product Trademarks in the Territory and, except with respect to the Vimovo Trademarks, which are addressed in the last sentence of this Section 5.6.1, will be responsible for the filing,
prosecution, maintenance and defense of all registrations of the Product Trademarks in the Territory, and will be responsible for the payment of any costs relating to filing, prosecution, maintenance and defense of the Product Trademarks in the
Territory. The Parties acknowledge and agree that AstraZeneca AB (or its Affiliate) is the sole owner of any Vimovo Trademark that may be used by Licensee in connection with POZEN Products in the Territory pursuant to a separate agreement between
Licensee and AstraZeneca AB, and that the filing, prosecution, maintenance and defense of all registrations of the Vimovo Trademarks in the Territory shall be governed by the terms of such separate agreement. 

5.6.2 Use. Licensee will use the Product Trademarks in connection with the Commercialization of POZEN Products hereunder. The
packaging, Promotional Materials and Product Labeling for POZEN Products will carry the POZEN House Marks only if and to the extent required by Applicable Law. 

5.6.3 Licensee Marks. Licensee reserves all rights in the Licensee House Marks. POZEN acknowledges Licensee’s exclusive right,
title and interest in and to such trademarks and acknowledges that nothing herein will be construed to accord to POZEN any rights in such trademarks. POZEN agrees not to use or file any application to register any trademark or trade name that is
confusingly similar to any Product Trademarks or Licensee House Mark. 

  
 -17- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 5.6.4 POZEN Marks. POZEN reserves all rights in the POZEN House Marks not expressly
granted to Licensee in this Agreement. Licensee acknowledges POZEN’s exclusive right, title and interest in and to the POZEN House Marks and acknowledges that nothing herein will be construed to accord to Licensee any rights in such trademarks
except as expressly provided herein. Licensee further acknowledges that its use of the POZEN House Marks will not create in Licensee any right, title or interest in such trademarks, and that all use of such trademarks and the goodwill generated
thereby will inure solely to the benefit of POZEN. Licensee agrees not to use or file any application to register any trademark or trade name that is confusingly similar to any POZEN House Mark. 

5.6.5 Promotional Materials. As between the Parties, Licensee will own all right, title and interest in and to any Promotional
Materials created by or on behalf of Licensee (or its Affiliates) relating to POZEN Product in the Territory, but excluding the POZEN House Marks. The PT will approve a standard template for use of the POZEN House Marks in Promotional Materials, and
Licensee will use the POZEN House Marks in accordance with approved template. 
 5.7 Commercial Supply. Licensee will be solely
responsible, at its own expense, for the Manufacture and supply of Licensee’s entire requirements of supplies of POZEN Product for Commercialization in the Territory. 
  

	6.	[INTENTIONALLY OMITTED] 

  

	7.	LICENSES 

 7.1 Licensed Technology. Subject to the terms and conditions of this
Agreement, POZEN hereby grants to Licensee an exclusive (including with regard to POZEN and its Affiliates), royalty-bearing license, with the right to grant sublicenses as described in Section 7.3 (Sublicenses), under the Licensed Technology to
make, use, have made, sell, offer for sale, import and export Products in the Field of Use in the Territory. For the avoidance of doubt, Licensee shall have no license or other right under the Licensed Technology to make, use, have made, sell, offer
for sale, import, and export any product containing acetyl salicylic acid (including salts and derivatives thereof). 
 7.2
Trademarks. Subject to the terms and conditions set forth in this Agreement, POZEN hereby grants to Licensee a license to use the POZEN House Marks in connection with the Commercialization of POZEN Products in the Field of Use in the Territory.

 7.3 Sublicenses. Licensee may grant a sublicense, option to sublicense, or any other right relating to any Licensed Technology to
any of its Affiliates without the right to grant further sublicense rights to any Third Party. Licensee may grant a sublicense, option to sublicense, or any other right relating to any Licensed Technology to any Third Party solely as provided in
this Section 7.3 (Sublicenses). Licensee may enter into Sublicense Agreements only with POZEN’s prior consent. In order for rights under Licensed Technology to be validly granted to a Sublicensee, the Sublicense Agreement with such Sublicensee
must be consistent with the following terms and conditions of this Agreement, and will include provisions for the benefit of POZEN corresponding to Section 11 (Confidentiality), 14 (Limitation of Liability), 8.2

  
 -18- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
(Payments and Sales Reporting), and 8.3 (Records; Audit). Except as set forth in that certain side letter agreement between POZEN and AstraZeneca AB dated September 16, 2013,
(a) Licensee will use Diligent Efforts to (i) procure the performance by any Sublicensee of the terms of each such Sublicense Agreement, and (ii) ensure that any Sublicensee will comply with the applicable terms and conditions of this
Agreement and (b) Licensee hereby guarantees the performance of its Affiliates and Sublicensees that are sublicensed as permitted herein, and the grant of any such sublicense will not relieve Licensee of its obligations under this Agreement,
except to the extent they are satisfactorily performed by such Affiliate or Sublicensee. Notwithstanding the foregoing, Licensee will have the right to sell POZEN Products through any distributors or sub-distributors of its choice, without the need
to obtain prior consent from POZEN, in carrying out its Commercialization activities under this Agreement. 
 7.4 Reservation of Rights;
No Implied Licenses. 
 (a) POZEN retains rights under the Licensed Technology to the extent necessary to perform its obligations
under this Agreement. Except for the rights specifically granted in this Agreement, POZEN reserves all rights to the Licensed Technology. No implied licenses are granted under this Agreement. In particular POZEN is not by this Agreement, by
implication or otherwise, granted any license or other right relating to Esomeprazole, Nexium or the Nexium Business or any Esomeprazole based products or any products containing acetyl salicylic acid (including salts and derivatives thereof) or any
right in relation to any patent, trademark or other intellectual property right belonging to Licensee or any of its Affiliates, and likewise Licensee is not by this Agreement, by implication or otherwise, granted any license or other right under the
Licensed Technology relating to any products containing acetyl salicylic acid (including salts and derivatives thereof) or any right in relation to any patent, trademark or other intellectual property right belonging to POZEN or any of its
Affiliates, in each case, except as expressly set forth in this Agreement. 
 (b) Licensee understands that POZEN has retained
rights to the Products outside the Territory and has licensed such rights to a Person under the ROW Agreement (the “ROW Party”). 

7.5 Restrictive Covenant. Licensee hereby covenants and agrees not to use any Licensed Technology, nor grant any Third Party any
license or right under any Licensed Technology, other than as expressly permitted in this Agreement. The Parties agree that nothing in this Agreement restricts or prohibits Licensee from by itself or with Third Parties exploiting any products,
including without limitation any products containing non-steroidal anti-inflammatory drugs (e.g., acetyl salicylic acid and esters and derivatives thereof); provided, that Licensee shall not use or practice Licensed Technology in connection
with the development, manufacture or commercialization of any product that is not a Product, and nothing requires Licensee to compensate POZEN if Licensee so exploits such products. 

  
 -19- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

	8.	FINANCIAL TERMS 

 8.1 Royalties. 

8.1.1 Royalty Rate. Subject to the terms and conditions of this Agreement, Licensee will pay to POZEN royalties based on the aggregate
annual Net Sales of Products sold by Licensee, its Affiliates or Sublicensees, at the rate of 10% of aggregate Net Sales of Products sold in the Territory. 

8.1.2 Royalty Term. Licensee acknowledges that it will continue to enjoy substantial benefit from its license under, and the transfer
to Licensee of certain elements of, the Licensed Technology pursuant to this Agreement (including the Licensed Know-How and the regulatory data to be provided to Licensee pursuant to this Agreement) as well as from Licensee’s own development of
technology derived from the practice of such license and Licensee’s use of such Licensed Technology, even after expiration of all Valid Claims of the Licensed Patents covering the composition of matter, manufacture, use or sale of POZEN Product
in the Territory. Accordingly, subject to the terms of Section 8.1.3 (Rate Step Down for Competing Product Entrants), Licensee’s royalty payment obligations under this Section 8.1 (Royalties) will commence upon First Commercial Sale of a
Product in the Territory and will expire upon the later of: (i) expiration of the last-to-expire Valid Claim of the Licensed Patents that, but for the licenses granted in this Agreement, would be infringed by the sale of such Product in the
Territory, and (ii) ten (10) years after the First Commercial Sale of such Product in the Territory (such period ending at the later of the periods set forth in clause (i) and (ii) above, the “Royalty Term”).

 8.1.3 Rate Step Down For Competing Product Entrants. With respect to any particular Product in the Territory, if in any Calendar
Quarter there is a Market Reduction of such Product (based on prescription market data published by IMS Health, Scott-Levin, or such other industry standard source as the Parties may agree), then the royalty rates which would otherwise apply to Net
Sales of such Product during such Calendar Quarter will be reduced to *** percent (***%). Such reduced royalty rates will continue in effect, on a Product-by-Product basis, until expiration of the applicable Royalty Term. As used in this
Section 8.1.3, the term “Market Reduction” of a Product in a Calendar Quarter occurs when (i) the cumulative share achieved by Competing Products for such Product commercialized by Third Parties in such *** of the *** in
the territory of the Product and Competing Products and (ii) the sales of the Product(s) in such *** are reduced by *** to the *** in which the *** of a Competing Product occurred. The example set forth in Schedule 8.1.3 illustrates the
application of this Section 8.1.3. 
 8.1.4 Third Party Payments. If Licensee or a Sublicensee determines that a license to certain
Third Party technology is reasonably necessary for the successful Development, Manufacture or Commercialization of a Product in the Territory, then Licensee will notify POZEN in writing of such determination. The Parties will consult in good faith
regarding the need for such Third Party technology and, subject to POZEN’s consent (not to be unreasonably withheld, conditioned or delayed), Licensee (or Sublicensee, if applicable) will negotiate the terms on which such a Third Party license
would be granted to Licensee and will serve as the primary point of contact with the applicable Third Party licensor following the execution of the license agreement. The royalties required to be paid by Licensee with respect to a Product pursuant
to Section 8.1 (Royalties) shall be subject to a reduction by Licensee in an amount equal to *** (***%) of the amount of *** that are *** under such *** in the *** for the 

  
 -20- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
*** of such *** during the *** provided, that (i) *** of the *** of such *** pursuant to *** for such ***, and (ii) if such *** is a *** (i.e., *** for such ***). For clarity,
and notwithstanding anything to the contrary in this Agreement, AstraZeneca AB and its Affiliates shall be solely responsible for any Third Party payment obligations it may have to Merck & Co., Inc. or its affiliates, without any offset or
deduction. Any amount of Third Party Royalties that may, pursuant to the preceding paragraph be used to reduce royalties due hereunder, in any Calendar Quarter, but are not so used as a result of the limitation described in clause (i) of this
paragraph may be carried over and used for further reduction in any succeeding royalty payment due for such Product. 

8.1.5***. 
 8.2
Payments and Sales Reporting. 
 8.2.1 Sales Reporting. Licensee will provide POZEN, within *** *** (***) of the end of
each Calendar Quarter, with a report setting forth, on a Product-by-Product basis, the amount of gross sales of each Product in the Territory, a calculation of Net Sales and a calculation of the amount of royalty payment due on such Net Sales,
provided that Licensee shall use reasonable efforts to provide such report as soon as practicable to accommodate POZEN’s SEC filing requirements and to provide such reports in a shorter time period than the periods specified above if Licensee
has such reports available for its own internal purposes. If any payment reduction is claimed by Licensee under this Agreement from the full royalty rates set forth in Section 8.1 (Royalties), then the report will set forth in detail the claimed
reduction and the related facts. 
 8.2.2 Payment Timing. Licensee will make royalty payments to POZEN within *** (***) days of the
last day of each Calendar Quarter for which such payments are due under Section 8.1 (Royalties). 
 8.2.3 Payment Method. All amounts
due hereunder will be paid in United States Dollars by wire transfer in immediately available funds to the following account, or such other account as may be designated in writing by POZEN: 

 

			
	Receiving bank name:	  	***
	Receiving bank address:	  	***
	ABA routing number (1):	  	*** (1) - required for domestic transfers
	SWIFT BIC address (2):	  	*** (2) - required for international transfers
	For credit to the account of:	  	POZEN Inc.
	For credit to account number:	  	***

 8.2.4 Currency. All payments required under this Article 8 shall be made in U.S. Dollars. 

8.2.5 Late Payments. If a Party does not receive payment of any sum due to it on or before the due date, simple interest will
thereafter accrue on the sum due to such Party until the date of payment at the per annum rate of *** percent (***%) over the then-current *** quoted by Citibank in New York City, or the maximum rate allowable by Applicable Law, whichever is lower.

  
 -21- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 8.3 Records; Audit. Licensee will maintain complete and accurate records in sufficient
detail to permit POZEN to confirm the accuracy of the calculation of payments under this Agreement. Upon reasonable prior notice, such records will be available during regular business hours of Licensee for a period of *** (***) calendar years
following the year in which such records were created, for examination at POZEN’s expense, and not more often than once each calendar year, by an independent certified public accountant selected by POZEN and reasonably acceptable to Licensee,
for the sole purpose of verifying the accuracy of the financial reports furnished by Licensee pursuant to this Agreement. Any such auditor will not disclose Licensee’s Confidential Information, except to the extent such disclosure is necessary
to verify the accuracy of the financial reports furnished by Licensee or the amount of payments due by Licensee under this Agreement. Any amounts shown to be owed but unpaid will be paid within *** (***) days from the accountant’s report, plus
interest (as set forth in Section 8.2.5 (Late Payments)) from the original due date. Any amounts determined to be overpaid will be refunded within *** (***) days from the accountant’s report. POZEN will bear the full cost of such audit unless
such audit discloses an underpayment of the amount actually owed during the applicable calendar year of more than *** percent (***%), in which case Licensee will bear the full cost of such audit. 

8.4 Taxes. 
 8.4.1
General. The royalties, milestones and other amounts payable by one Party to the other Party pursuant to this Agreement or the Three-Party Agreement (“Payments”) shall not be reduced on account of any taxes unless required by
Applicable Law. The Party receiving any Payment shall be responsible for paying any and all taxes (other than withholding taxes or deduction of tax at source required by Applicable Law to be paid by the paying Party) levied on account of, or
measured in whole or in part by reference to, any Payments it receives. The paying Party shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the Party
receiving payment is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to the paying Party or the appropriate governmental authority (with the assistance of the
paying Party to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding tax or to relieve the paying Party of its obligation to withhold tax, and
the paying Party shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that the paying Party has received evidence, in a form satisfactory to the paying Party, of the other Party’s
delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least *** (***) days prior to the time that the Payments are due. If, in accordance with the foregoing, the paying Party withholds any
amount, it shall pay to the other Party the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to the other Party proof of such payment within *** (***) days following that payment. 

  
 -22- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 8.4.2 Indirect Taxes. Notwithstanding anything contained in Section 8.4.1 (General),
this Section 8.4.2 (Indirect Taxes) shall apply with respect to Indirect Taxes. All Payments are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, the paying Party shall pay the Indirect Taxes at the
applicable rate in respect of any such Payments following the receipt of an Indirect Taxes invoice in the appropriate form issued by the Party receiving Payments in respect of those Payments, such Indirect Taxes to be payable on the due date of the
payment of the Payments to which such Indirect Taxes relate. 
  

	9.	INTELLECTUAL PROPERTY 

 9.1 Prosecution and Maintenance of Licensed Patents. POZEN
will be responsible for the preparation, filing, prosecution and maintenance of the Licensed Patents (other than Joint Patents), at its own expense. POZEN will provide a copy of all proposed filings at least *** (***) days in advance of the filing
date and will consider in good faith the requests and suggestions of Licensee with respect to filing and prosecuting the Licensed Patents and will keep Licensee promptly informed of progress with regard to the preparation, filing, prosecution and
maintenance of Licensed Patents. In the event that POZEN desires to abandon any Licensed Patent, POZEN will provide reasonable prior written notice to Licensee of such intention to abandon (which notice will, in any event, be given no later than ***
(***) days prior to the next deadline for any action that may be taken with respect to such Licensed Patent with the U.S. Patent & Trademark Office), and Licensee will have the right to assume responsibility for such Licensed Patent. For
clarity, any Patent with Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, Licensee will have no right to assume responsibility for such Patent
as provided under this Section 9.1 should Pozen decide to abandon such Patent. 
 9.2 Prosecution and Maintenance of Joint Patents.
Licensee will be responsible for the preparation, filing, prosecution and maintenance of Joint Patents, at its own expense. Licensee will provide to POZEN a copy of all proposed filings at least *** (***) days in advance of the filing date and will
consider in good faith the requests and suggestions of POZEN with respect to filing and prosecuting the Joint Patents and will keep POZEN promptly informed of progress with regard to the preparation, filing, prosecution and maintenance of Joint
Patents. In the event that Licensee desires to abandon any Joint Patent, Licensee will provide reasonable prior written notice to POZEN of such intention to abandon (which notice will, in any event, be given no later than *** (***) days prior to the
next deadline for any action that may be taken with respect to such Joint Patent with the U.S. Patent & Trademark Office), and POZEN will have the right to assume responsibility for such Joint Patent. 

9.3 Ownership of Inventions. Inventorship of Inventions will be determined in accordance with the rules of inventorship under United
States patent laws. Subject to the licenses granted under this Agreement, as between the Parties, Licensee will own all Licensee Inventions, POZEN will own all POZEN Inventions, and Joint Inventions will be owned jointly by Licensee and POZEN;
provided, however, that during the Term of this Agreement: (i) neither POZEN nor Licensee shall *** other than as expressly provided in this Agreement, including Section 7.1 (Licensed Technology), without the consent of the other
Party, which consent shall not be unreasonably withheld, conditioned or delayed, and (ii) neither Party shall assign, pledge, encumber, license or otherwise transfer any of its rights in any Joint Invention or Joint Patent without the other
Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. Upon any expiration or termination of this Agreement, each 

  
 -23- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
Party will have the right to exploit, license and grant rights to sublicense each such Joint Invention and Joint Patent, without any duty of accounting to the other Party, and each Party hereby
consents, and agrees to consent, without payment of any further consideration or royalty, to the Joint Party’s exploitation and licensing of said Joint Party’s interest in such Joint Invention or Joint Patent to Third Parties; provided,
that nothing in this Section 9.3 gives either Party any right or license under any intellectual property rights Controlled by the other Party other than Joint Inventions and Joint Patents, regardless of whether such rights are necessary in
order to exploit the Joint Inventions and Joint Patents pursuant to this Section 9.3. The Parties acknowledge and agree that AstraZeneca AB owns all AstraZeneca Inventions (as defined in the Original Agreement) conceived under the Original
Agreement in the performance of activities undertaken pursuant to the Original Agreement solely by employees, agents, or independent contractors of AstraZeneca AB, its Affiliates or sublicensees prior to the Amended and Restated Effective Date. 

9.4 Disclosure. Each Party will promptly disclose to the other Party in writing, and will cause its Affiliates, agents, and independent
contractors to so disclose to the other Party, the conception and reduction to practice of any Invention. 
 9.5 Cooperation. Each
Party acknowledges the importance of securing and maintaining effective patent protection for the Licensed Technology and Joint Patents. Each Party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of the Licensed
Patents and Joint Patents and in the obtaining and maintenance of any patent extensions, supplementary protection certificates and the like with respect to the Licensed Patents and Joint Patents. Such cooperation includes, but is not limited to:
(a) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to effectuate the ownership of Inventions set forth in Section 9.3 (Ownership of Inventions), and Patents in
the Territory claiming or disclosing such Inventions, and to enable the other Party to apply for and to prosecute patent applications in the Territory; and (b) promptly informing the other Party of any matters coming to such Party’s
attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications. 
 9.6 Enforcement of
Licensed Patents. 
 9.6.1 Infringement by Third Parties. Licensee and POZEN will each, within *** (***) Business Days of learning
of any alleged or threatened infringement of the Licensed Patents or Joint Patents, notify the other Party in writing. *** will have the first right, but not the obligation, to prosecute any such infringement. If *** does not commence an
infringement action against the alleged or threatened infringement (i) within *** (***) days following the detection of the of alleged infringement, or (ii) *** (***) Business Days before the time limit, if any, set forth in appropriate
laws and regulations for filing of such actions, whichever comes first, then *** will so notify *** promptly, and *** may commence litigation with respect to the alleged or threatened infringement at its own expense. For clarity, any Patent with
Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, *** will have no right to prosecute any infringement of such Patent under this Section 9.6.1.
Notwithstanding anything in this Section 9.6.1 to the contrary, *** shall not have the right to prosecute an infringement action under this Section 9.6.1 unless such action involves a Product. 

  
 -24- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 9.6.2 Challenge by Third Parties. Licensee and POZEN will each notify the other Party
in writing within *** (***) Business Days of learning of any alleged or threatened opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability of the
Licensed Patents or Joint Patents by a Third Party. *** will have the first right, but not the obligation, to defend any such challenge. If *** does not commence Diligent Efforts to defend against the alleged or threatened challenge (i) within
*** (***) days following the detection of the alleged challenge, or (ii) *** (***) Business Days before the time limit, if any, set forth in appropriate laws and regulations for making a filing in defense of such a challenge, whichever comes
first, then *** will so notify *** promptly, and *** may take action with respect to the alleged or threatened challenge at its own expense. For clarity, any Patent with Valid Claims solely directed to any product containing acetyl salicylic acid
(including salts and derivatives thereof) is not a Licensed Patent; therefore, *** will have no right to defend any challenge of such Patent under this Section 9.6.2. 

9.6.3 Cooperation. In the event a Party brings an infringement action pursuant to Section 9.6.1 (Infringement by Third Parties),
the other Party will cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or to join such action as a necessary party, executing all papers and instruments, or requiring its employees or contractor, to
execute such papers and instruments, so as to successfully prosecute any such actions. Neither Party will have the right to settle any patent infringement litigation under this Section 9.6.3 (Cooperation) in a manner that could be reasonably
expected to diminish the rights or interest of the other Party, or adversely effect the validity or enforceability of such other Party’s Patents, without the express written consent of such other Party. The Party commencing the litigation will
provide the other Party with copies of all pleadings and other documents filed with the court and will consider reasonable input from the other Party during the course of the proceedings. 

9.6.4 Recovery. Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a
result of such litigation described in Section 9.6.1 (Infringement by Third Parties) (whether by way of settlement or otherwise) will be first allocated to reimbursement of unreimbursed legal fees and all litigation expenses incurred by the Party
initiating the proceeding, then toward reimbursement of any of unreimbursed legal fees and all litigation expenses of the other Party, and then the remainder will be divided between the Parties as follows: (a) settlements, damages or other
monetary awards recovered pursuant to a suit, action or proceeding brought by *** will be *** and subject to *** set forth in ***; and (b) settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought
by *** will be ***. 
 9.7 Defense of Infringement Claims. If the manufacture, sale or use of a POZEN Product pursuant to this
Agreement results in any claim, suit, or proceeding by a Third Party alleging that such activities infringe a Third Party patent, or if a Third Party threatens such a claim, suit or proceeding, each Party will promptly notify the other Party
thereof. *** *** will have the exclusive right to defend and control the defense of any such claim, suit or proceeding at its own expense, using counsel of its own choice; provided, that if any such proceedings involve matters relating to the
validity or enforceability of the Licensed Patents or Joint Patents, then the provisions of Section 9.6.3 (Cooperation) above shall apply. In any claim, suit or proceeding under this Section 9.7, *** will keep *** reasonably informed of all material

  
 -25- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
developments in connection with any such claim, suit, or proceeding; provided, that if *** is named as a defendant in any such claim, suit or proceeding, that *** shall have the right to
participate in the defense using counsel of its choice at its own expense. In any claim, suit or proceeding under this Section 9.7, *** agrees to provide *** with copies of all pleadings filed in such action and to allow *** reasonable opportunity
to participate in the defense of the claims. 
 9.8 Patent Term Extension and Supplementary Protection Certificate. Upon receiving
Marketing Approval for a POZEN Product, the Parties agree to coordinate the application for any patent term extension or supplementary protection certificates that may be available. The primary responsibility of applying for any extension or
supplementary protection certificate will be the Party having the right to make the application under the Applicable Law. The Party responsible for filing the application will keep the other Party fully informed of its efforts to obtain such
extension or supplementary protection certificate. Each Party will provide prompt and reasonable assistance, without additional compensation, to obtain such patent extension or supplementary protection certificate. The Party filing such request will
pay all expenses in regard to obtaining the extension or supplementary protection certificate. 
 9.9 Consequence of Patent
Challenge. If Licensee or its Affiliates challenge the validity or enforceability of any of the Licensed Patents by any opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the
validity, title or enforceability thereof before any governmental agency, court or other similar adjudicative forum (any such proceeding, a “Patent Challenge”), such Patent Challenge shall give POZEN the right to terminate this
Agreement as provided in Section 12.3 (Termination for Material Breach) or to terminate all licenses granted under any of the Licensed Patents subject to such Patent Challenge; provided, that the foregoing provisions of this Section 9.9 (Consequence
of Patent Challenge) will not apply in the event that, prior to such Patent Challenge, POZEN or any of its licensees or assignees initiates or threatens litigation against, or makes claims or assertions against, Licensee or its Affiliates,
Sublicensees or Third Party contractors, that allege that any of such parties infringe a Licensed Patent. 
 9.10 Patent Certifications.

 9.10.1 Orange Book Listings. To the extent required or permitted by Applicable Law, Licensee will use Diligent Efforts to
promptly list and maintain with the applicable Regulatory Authorities in the Territory during the Term correct and complete listings of applicable Licensed Patents for such POZEN Product, including all so called “Orange Book” listings
required under the Hatch-Waxman Act. ***. 
 9.10.2 Hatch-Waxman Act. Notwithstanding Section 9.6.1 (Infringement by Third
Parties) above, each Party will immediately give notice to the other Party of any notice it receives of certification filed under the Hatch-Waxman Act claiming that any of the Licensed Patents is invalid, unenforceable or that any infringement will
not arise from the manufacture, use or sale of the POZEN Product by a Third Party. If Licensee decides not to bring infringement proceedings against the entity making such a certification with respect to any such Licensed Patents, Licensee will give
notice to POZEN of its decision not to bring suit within *** (***) Business Days after receipt of notice of such certification (or, if the time period permitted by law is less than *** (***) Business Days, within *** of the time period permitted by
law for 

  
 -26- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
Licensee to commence such action). POZEN may then, but is not required to, bring suit against the Third Party that filed the certification. Any suit by either Party may be in the name of either
or both Parties, as may be required by law. For this purpose, the Party not bringing suit will execute such legal papers necessary for the prosecution of such suit as may be reasonably requested by the Party bringing suit. For clarity, any Patent
with Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, Licensee will have no right to bring infringement proceedings of such Patent under this
Section 9.10.2. Notwithstanding anything in this Section 9.10.2 to the contrary, Licensee shall not have the right to bring an infringement proceeding under this Section 9.10.2 unless such proceeding involves a POZEN Product. 

9.11 Patent Marking. Any POZEN Product marketed and sold by Licensee under this Agreement will be marked with appropriate patent
numbers or indicia as permitted or required by law. The Parties agree to cooperate to reach a decision on the marking requirements. 
  

	10.	REPRESENTATIONS, WARRANTIES; COVENANTS 

 10.1 POZEN Representations and
Warranties. POZEN hereby warrants and represents to Licensee as of the Amended and Restated Execution Date and the Amended and Restated Effective Date that POZEN is the sole and exclusive owner of the Licensed Patents and has the right to
perform its obligations hereunder and to grant to Licensee the rights and licenses set forth in this Agreement in and to the Licensed Technology. 

10.2 Reciprocal Representations and Warranties. Each Party represents and warrants to the other Party that: (a) this Agreement is
a legal and valid obligation binding upon its execution and enforceable against it in accordance with its terms and conditions; and (b) the execution, delivery and performance of this Agreement by such Party has been duly authorized by all
necessary corporate action, and the person executing this Agreement on behalf of such Party has been duly authorized to do so by all requisite corporate actions. 

10.3 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTIONS 10.1 (POZEN WARRANTIES) AND
10.2 (RECIPROCAL REPRESENTATIONS AND WARRANTIES),EACH PARTY MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND POZEN AND LICENSEE EACH SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY OR MERCHANTABILITY, OR ANY WARRANTY AS TO THE VALIDITY OR ENFORCEABILITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. 
 10.4 POZEN Non-Compete. POZEN covenants that it will not at any time prior to the expiration of the Royalty
Term, and will ensure that its Affiliates do not, directly or indirectly, develop or commercialize or license any Third Party to develop or commercialize any product having a ***. Without limiting Licensee’s rights under this Agreement or
otherwise, in case of any breach of this 10.4 (POZEN Non-Compete), Licensee will notify POZEN and, if such breach is not cured by POZEN within *** (***) days after receipt of such notice, ***. 

  
 -27- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 10.5 Other Covenants. 

10.5.1 POZEN will not enter into any agreement, whether written or oral with respect to, or otherwise assign, transfer, license, convey
or otherwise encumber its rights, title or interest in the Licensed Technology (including by granting any covenant not to sue with respect thereto) to any Person in a manner that is inconsistent with the rights and licenses granted to Licensee under
this Agreement. 
 10.5.2 Each Party will obtain from each of its Affiliates, sublicensees, employees and agents and from the
employees and agents of its Affiliates, sublicensees and agents who are or will be involved in the Development of the POZEN Products or of the Licensed Technology, rights to any and all inventions, information, and intellectual property rights
conceived in the course of performance of this Agreement, necessary to enable such Party to grant the licenses and other rights granted to the other Party under this Agreement. 

 

	11.	CONFIDENTIALITY. 

 11.1 Definition. “Confidential Information” means
information, including scientific and manufacturing information and plans, marketing and business plans, and financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or
business, communicated by a Party (a “Disclosing Party”) to the other Party (a “Receiving Party”) (a) after the Amended and Restated Effective Date in connection with this Agreement or the performance of its
obligations hereunder or (b) in connection with (i) that certain confidentiality agreement between POZEN and AstraZeneca AB dated as of March 27, 2006, (ii) that certain confidentiality agreement between POZEN and AstraZeneca AB
dated as of June 15, 2006 or (iii) the Original Agreement, in each case ((i), (ii) and (iii)), except to the extent that such information relates exclusively to the exploitation of Products outside the Territory. Notwithstanding the
foregoing or any other provision of this Agreement to the contrary, during the Term, the Licensed Know-How will be deemed to be the Confidential Information of both Parties. 

11.2 Exclusions. Notwithstanding the foregoing, information of a Disclosing Party will not be deemed Confidential Information with
respect to a Receiving Party for purposes of this Agreement to the extent the Receiving Party can demonstrate by competent evidence that such information: 

11.2.1 was already known to the Receiving Party or its Affiliates, as evidenced by their written records, other than under an
obligation of confidentiality or non-use, at the time of disclosure to the Receiving Party; 
 11.2.2 was generally available or was
otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

  
 -28- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 11.2.3 became generally available or otherwise became part of the public domain after
its disclosure to the Receiving Party, through no fault of or breach of its obligations under this Section 11 (Confidentiality) by the Receiving Party; 

11.2.4 was disclosed to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality or non-use, by
a Third Party who had no obligation to the Party that controls such information and know-how not to disclose such information or know-how to others; or 

11.2.5 was independently discovered or developed by the Receiving Party or its Affiliates, as evidenced by their written records,
without the use of, and by personnel who had no access to, Confidential Information belonging to the Party that controls such information and know-how. 

11.3 Disclosure and Use Restriction. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
parties, the parties agree that, during the Term and for *** (***) years thereafter, the Receiving Party will keep confidential and will not publish or otherwise disclose and will not use for any purpose other than as expressly provided for in this
Agreement any Confidential Information of the Disclosing Party. The Receiving Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement or in connection with the exercise of its rights
hereunder. The Receiving Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its employees, agents, consultants and other representatives do not disclose or make
any unauthorized use of the Confidential Information. The Receiving Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information. 

11.4 Authorized Disclosure. A Receiving Party may disclose Confidential Information of a Disclosing Party to the extent that such
disclosure is: 
 11.4.1 made in response to a valid order of a court of competent jurisdiction or other governmental or regulatory
body of competent jurisdiction; provided, however, that such Receiving Party will have given notice to the Disclosing Party within *** (***) Business Days of receipt of such order and given the Disclosing Party a reasonable opportunity to
quash such order and to obtain a protective order requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or governmental or regulatory body or, if disclosed, be used only for
the purposes for which the order was issued; and provided, further, that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order will
be limited to that information which is legally required to be disclosed in response to such court or governmental order; 
 11.4.2
otherwise required by law; provided, that the Disclosing Party will provide the Receiving Party with notice of such disclosure at least *** (***) days in advance thereof to the extent practicable and take reasonable steps as requested by
the Disclosing Party to protect the Disclosing Party’s rights; 

  
 -29- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 11.4.3 made by a Receiving Party, in connection with the performance of this
Agreement, (a) to Affiliates, employees, consultants, representatives or agents, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 11
(Confidentiality) or (b) to Regulatory Authorities in the Territory (provided, that in the case of disclosures to Regulatory Authorities, the Receiving Party will, to the extent practicable, provide the Disclosing Party with notice of
such disclosure at least *** (***) days in advance thereof and will reasonably consider any comments received from the Disclosing Party); 

11.4.4 made by a Receiving Party to existing or potential acquirers or merger candidates; potential sublicensees or collaborators (to
the extent contemplated hereunder); investment bankers; existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing; or Affiliates, each of whom prior to disclosure must be
bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 11 (Confidentiality); or 

11.4.5 made by the Receiving Party with the prior written consent of the Disclosing Party. 

11.5 Use of Name. Neither Party may make public use of the other Party’s name except (a) in connection with announcements and
other disclosures relating to this Agreement and the activities contemplated hereby as permitted in Section 11.6 (Press Releases), (b) as required by Applicable Law, and (c) otherwise as agreed in writing by such other Party. 

11.6 Press Releases. 

11.6.1 On or after the Amended and Restated Effective Date of this Agreement at a mutually agreed time, each Party (including, for
clarity, Horizon as assignee of Licensee in connection with the Divestiture) will issue a mutually agreed press release announcing the existence of this Agreement each in the form and substance to be mutually agreed upon in advance. For subsequent
press releases and other written public disclosures relating to this Agreement or the Parties’ relationship hereunder (each, a “Public Disclosure”), each Party will use reasonable efforts to submit to the other Party a draft of
such Public Disclosures for review and comment by the other Party at least *** (***) Business Days prior to the date on which such Party plans to release such Public Disclosure, and in any event will submit such drafts at least *** *** prior to the
release of such Public Disclosure, and will review and consider in good faith any comments provided in response. 
 11.6.2 If a Party
is unable to comply with the foregoing *** notice requirement because of a legal obligation or stock exchange requirement to make more rapid disclosure, such Party will not be in breach of this Agreement but will in that case provide notice as
promptly as practicable under the circumstances. 
 11.6.3 A Party may publicly disclose, without regard to the preceding
requirements of this Section 11.6 (Press Releases), information that was previously disclosed in a Public Disclosure that was in compliance with such requirements. 

  
 -30- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 11.7 Terms of Agreement to be Maintained in Confidence. The Parties agree that the
terms of this Agreement are confidential and will not be disclosed by either Party to any Third Party (except to a Party’s professional advisors, including without limitation accountants, financial advisors, and attorneys) without prior written
permission of the other Party; provided, however, that (a) either Party may make any filings of this Agreement required by law or regulation in any country so long as such Party uses its reasonable efforts to obtain confidential treatment for
portions of this Agreement as available, consults with the other Party, and permits the other Party to participate, to the greatest extent practicable, in seeking a protective order or other confidential treatment; (b) either Party may disclose
this Agreement on a confidential basis to existing or potential Third Party investors, lenders or acquirors or, in the case of Licensee, to existing or potential Sublicensees, in each case in connection with due diligence or similar investigations;
and (c) a Party may publicly disclose, without regard to the preceding requirements of this Section 11.7, information that was previously disclosed in compliance with such requirements. 

 

	12.	TERM AND TERMINATION 

 12.1 Amended and Restated Effective Date. This Agreement
(other than this Section 12.1, which is binding and effective as of the Amended and Restated Execution Date), shall not become effective unless and until the closing of a Divestiture occurs (the date of such closing, the “Amended and
Restated Effective Date”), and upon the Amended and Restated Effective Date this Agreement and all of its terms and provisions shall be automatically effective and binding on both Parties. The Original Agreement shall not be amended and
restated or otherwise superseded by this Agreement until the Amended and Restated Effective Date. If the Amended and Restated Effective Date has not occurred by December 31, 2013, then this Agreement, including this Section 12.1, shall
terminate and be of no further force and effect. For clarity, such termination will not give rise to any of the effects or consequences set forth in Section 12.5. 

12.2 Term. The term of this Agreement will commence as of the Effective Date and, unless earlier terminated in accordance with
this Section 12 (Term and Termination), will expire upon the expiration of the Royalty Term for all POZEN Products in the Territory (the “Term”). 

12.3 Termination for Material Breach. In the event that either Party (the “Breaching Party”) shall be in material
default of any of its material obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement in its entirety by
*** (***) days prior written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate; provided, that the termination shall not become effective at the end of the Notice Period
if the Breaching Party cures the breach complained about during the Notice Period (or, if such default cannot be cured within such Notice Period, if the Breaching Party commences actions to cure such default within the Notice Period and thereafter
diligently continues such actions). It is understood that termination pursuant to this Section 12.3 (Termination for Material Breach) shall be a remedy of last resort and may be invoked only in the case where the breach cannot be reasonably remedied
by the payment of money damages or other remedy under applicable law. If either Party initiates a dispute resolution procedure as permitted under this Agreement prior to the end of the Notice Period to

  
 -31- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
resolve the dispute for which termination is being sought and is diligently pursuing such procedure, including any litigation following therefrom, the termination shall become effective only if
and when such dispute is finally resolved through such dispute resolution procedure. This Section 12.3 (Termination for Material Breach) defines exclusively the Parties’ right to terminate in case of any material breach of this Agreement. 

12.4 Termination for Cause. If a Post-Approval Failure occurs in the Territory, Licensee may, at its option, terminate the Agreement in
its entirety; provided, that written notice of termination must be delivered to POZEN within ***(***) days following such Post-Approval Failure. 

12.5 Consequences of Expiration and Termination. 

12.5.1 Effect of Expiration. Upon expiration (but not earlier termination) of the Term pursuant to Section 12.2 (Term), Licensee will
have a non exclusive, irrevocable, perpetual, fully-paid license, with the right to sublicense, under the Licensed Technology to research, develop, make, use, sell, offer for sale, and import the POZEN Product in the Field of Use in the Territory.

 12.5.2 Effect of Termination. The use by either party hereto of a termination right provided for under this Agreement and in
accordance with this Agreement shall not give rise to the payment of damages or any other form of compensation or relief to the other party with respect thereto. Subject to the preceding sentence, termination of this Agreement shall not preclude
either party from claiming any other damages, compensation or relief that it may be entitled to upon such termination or for any breach of this Agreement. If either Party terminates this Agreement, all rights and licenses granted by POZEN to
Licensee and all obligations of Licensee and POZEN under this Agreement will terminate immediately. 
 12.6 Termination for
Insolvency. This Agreement may be terminated by written notice by either Party at any time during the Term upon the declaration by a court of competent jurisdiction that the other Party is bankrupt and, pursuant to the U.S. Bankruptcy Code such
other Party’s assets are to be liquidated; upon the filing or institution of bankruptcy, liquidation or receivership proceedings (other than reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code); or upon an assignment of a
substantial portion of the assets for the benefit of creditors by the other Party; or in the event a receiver or custodian is appointed for such Party’s business; provided, however, that in the case of any involuntary proceeding, such right to
terminate shall only become effective if the proceeding is not dismissed within 60 days after the filing thereof (each of the foregoing, a “Bankruptcy Event”). 

12.7 Effect of Bankruptcy. All rights and licenses with respect to Patents and Know-How granted under or pursuant to this Agreement by
one Party to the other Party are, for all purposes of Section 365(n) of Title 11 of the United States Code (“Title 11”), licenses of rights to “intellectual property” as defined in Title 11. Each Party agrees that the
other Party, as licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under Title 11. POZEN *** Licensee *** POZEN *** POZEN *** (i) *** (ii) *** (iii) *** (iv) ***
(v) *** (vi) ***, and (vii) ***, and (viii) ***. POZEN agrees not to interfere with Licensee and its Affiliates’ exercise of rights and licenses to intellectual property 

  
 -32- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
licensed hereunder and embodiments thereof in accordance with this Agreement and agrees to use commercially reasonable efforts to assist Licensee and its Affiliates to obtain such intellectual
property and embodiments thereof in the possession or control of Third Parties as reasonably necessary or desirable for Licensee or its Affiliates to exercise such rights and licenses in accordance with this Agreement. Each party agrees and
acknowledges that all payments by Licensee to POZEN payable under this Agreement other than royalty payments pursuant to Section 8.1 (Royalties) and commercialization milestone payments under the Three-Party Agreement do not constitute
“royalties” within the meaning of Section 365(n) of Title 11 or relate to licenses of intellectual property hereunder. 

12.8 Formulation Technology. If Licensee terminates this Agreement for any reason other than for material breach by POZEN under
Section 12.3 or as a result of POZEN’s insolvency under Section 12.7, then, subject to the terms and conditions of this Agreement, Licensee agrees to grant to POZEN, and does hereby grant effective automatically upon such termination,
(a) a perpetual, irrevocable, non-exclusive license or sublicense under the Formulation Technology, with the right to grant sublicenses and authorize the grant of sublicenses to the extent provided in this Section 12.8, to make, have made,
use, sell, offer for sale, and import POZEN Products in the Territory and (b) a perpetual, irrevocable, non-exclusive license or sublicense, as applicable, under the Formulation Technology, with the right to grant sublicenses and authorize the
grant of sublicenses to the extent provided in this Section 12.8, to Develop and Manufacture (but not sell or otherwise Commercialize) POZEN Products outside the Territory solely in support of the Development or Commercialization of the POZEN
Products in the Territory; provided, that nothing herein gives POZEN any right or license under any other intellectual property rights Controlled by Licensee, regardless of whether such rights are necessary in order to exploit the Formulation
Technology pursuant to this Section 12.8. POZEN may grant sublicenses and the right to grant further sublicenses under the foregoing license only as follows: (i) for any sublicense relating to the development or commercialization of a
POZEN Product Commercialized by Licensee in the Territory at the time of such termination (a “Commercialized POZEN Product”) in the Territory, POZEN may grant such sublicense upon notice to Licensee, but without obtaining
Licensee’s consent, and (ii) for any sublicense relating to POZEN Products other than Commercialized POZEN Products in the Territory, POZEN may grant such sublicense with Licensee’s prior written consent (such consent not to be
unreasonably withheld, conditioned or delayed). 
 12.9 Survival. Expiration or termination of this Agreement will not relieve the
Parties of any obligation accruing prior to such expiration or termination. The provisions of Sections 8.1 (Royalties), 8.2 (Payments and Sales Reporting), 8.3 (Records; Audits), 9.2 (Prosecution and Maintenance of Joint Patents), 9.3 (Ownership of
Inventions), 10.3 (Disclaimer of Warranty), 11 (Confidentiality), 12.5 (Consequences of Expiration and Termination), 12.7 (Effect of Bankruptcy), 12.8 (Formulation Technology), 12.9 (Survival), 13 (Indemnification and Insurance), 14 (Limitation of
Liability), and 15 (Miscellaneous) will survive any termination or expiration of this Agreement (other than a termination pursuant to Section 12.1). 

  
 -33- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

	13.	INDEMNIFICATION AND INSURANCE 

 13.1 Indemnification by POZEN. POZEN hereby agrees
to save, defend and hold Licensee and its Affiliates and their respective directors, officers, employees and agents (each, a “Licensee Indemnitee”) harmless from and against any and all claims, suits, actions, demands, liabilities,
expenses and/or loss, including reasonable legal expense and attorneys’ fees (collectively, “Losses”), to which any Licensee Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any
Third Party to the extent such Losses arise directly or indirectly out of: (i) the gross negligence or willful misconduct of any POZEN Indemnitee or (ii) the breach by POZEN of any warranty, representation, covenant or agreement made by
POZEN in this Agreement; except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Licensee Indemnitee or the breach by Licensee of any warranty, representation, covenant or agreement made by
Licensee in this Agreement. 
 13.2 Indemnification by Licensee. Licensee hereby agrees to save, defend and hold POZEN and its
Affiliates and their respective directors, officers, employees and agents (each, an “POZEN Indemnitee”) harmless from and against any and all Losses to which any POZEN Indemnitee may become subject as a result of any claim, demand,
action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (i) the development, manufacture, use, handling, storage, sale or other disposition of any Product by Licensee, its Affiliates or any
of their respective Sublicensees, (ii) the gross negligence or willful misconduct of any Licensee Indemnitee, or (iii) the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement, in
each case ((i), (ii) and (iii)), after the Amended and Restated Effective Date; except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any POZEN Indemnitee or the breach by POZEN of any
warranty, representation, covenant or agreement made by POZEN in this Agreement. 
 13.3 Indemnification Procedure. 

13.3.1 Notice of Claim. The indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt
written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 13.1 (Indemnification by POZEN) or
Section 13.2 (Indemnification by Licensee); provided, however, that the failure to give such prompt written notice will not relieve Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent
that the Indemnifying Party is actually prejudiced as a result of such failure. In no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a
description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The indemnified Party will furnish promptly to the indemnifying Party copies of all papers and official
documents received in respect of any Losses. All indemnification claims in respect of a Party, its Affiliates or their respective directors, officers, employees and agents (collectively, the “Indemnitees” and each an
“Indemnitee”) will be made solely by such Party to this Agreement (the “Indemnified Party”). 
 13.3.2
Control of Defense. At its option, the Indemnifying Party may assume the defense of any claim for which indemnification is sought (a “Third Party Claim”) by giving written notice to the Indemnified Party within *** (***) days
after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any

  
 -34- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
legal counsel selected by the Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the
Indemnifying Party all original notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party will
not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 

13.3.3 Right to Participate in Defense. Without limiting Section 13.3.2 (Control of Defense) above, any Indemnitee will be entitled to
participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnitee’s own expense unless (i) the employment
thereof has been specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 13.3.2 (Control of Defense) (in which case the
Indemnified Party will control the defense). 
 13.3.4 Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the
Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of
such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to the time prior to the entry of
judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 13.3.2 (Control of Defense), the Indemnifying Party will have
authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s sole and
absolute discretion). The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party
chooses to defend or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without the prior written consent of the Indemnifying Party. 

13.3.5 Cooperation. The Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense or prosecution
thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with the defense or prosecution of
any Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third
Party 

  
 -35- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the
Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 
 13.4
Expenses. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter basis by
the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to
indemnify the Indemnified Party. 
 13.5 Insurance. Each Party will have and maintain such types and amounts of liability insurance
as is normal and customary in the industry generally for parties similarly situated, and will upon request provide the other Party with a copy of its policies of insurance in that regard, along with any amendments and revisions thereto. 

 

	14.	LIMITATION OF LIABILITY 

 IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS, LOSS
OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND
ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT AND WILL NOT LIMIT EITHER PARTY’S LIABILITY TO THE OTHER PARTY
UNDER SECTIONS 7.5 (RESTRICTIVE COVENANT), 10.4 (POZEN NON-COMPETE), 11 (CONFIDENTIALITY), AND 13 (INDEMNIFICATION AND INSURANCE) OF THIS AGREEMENT. 
  

	15.	MISCELLANEOUS 

 15.1 Assignment. 

15.1.1 Without the prior written consent of the other Party hereto (which may be granted at the other Party’s discretion), neither
Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that either Party
hereto may assign or transfer this Agreement or any of its rights or obligations hereunder without the consent of the other Party (a) to any Affiliate of such Party; or (b) in connection with the transfer or sale of all or substantially
all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise. Except as set forth in that certain side letter agreement between POZEN and AstraZeneca AB dated
September 16, 2013, the assigning Party (except if it is not the surviving entity) will remain jointly and severally liable with the relevant Affiliate or Third Party assignee under this Agreement, and the relevant Affiliate assignee, Third
Party assignee or surviving entity will assume in writing all of the assigning Party’s obligations under this Agreement. Any purported assignment or transfer in violation of this Section 15.1 (Assignment) will be void ab initio and
of no force or effect. 

  
 -36- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 15.1.2 In the event that POZEN desires to sell all or a part of its rights to receive
payments under this Agreement, then upon POZEN’s written request, Licensee shall enter into a consent in substantially the form of the Consent Agreement attached hereto as Schedule 15.1.2 with respect to such transaction. 

15.2 Termination of Certain Rights Upon POZEN Change of Corporate Control. POZEN shall promptly notify Licensee in writing following
consummation of a Change of Corporate Control of POZEN. Notwithstanding anything else in this Agreement to the contrary, in the event of a Change of Corporate Control of POZEN, then Licensee will have the right, exercisable by written notice to
POZEN or its successor in interest given within *** (***) days after Licensee receives written notice from POZEN of the completion of such Change of Corporate Control: (a) to terminate *** established pursuant to this Agreement; and (b) to
terminate its obligation to make *** to POZEN pursuant to this Agreement other than *** and as reasonably required to ***; subject, in each case, to Licensee’s continued compliance with all applicable provisions of this Agreement (including,
without limitation, Articles 8, 9 and 11). POZEN shall cooperate in providing to Licensee all information, assistance, assignments and other support reasonably requested to assist Licensee in assuming such control. For purposes of clarification, all
Confidential Information of Licensee in POZEN’s or its successor’s possession following Licensee’s exercise of its rights under this Section 15.2 shall continue to be subject to all applicable provisions of this Agreement
(including, without limitation, Articles 7 and 11). 
 15.3 Severability. If any provision of this Agreement is held to be illegal,
invalid or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this
Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by
the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable
provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law
that would render any provision prohibited or unenforceable in any respect. 
 15.4 Governing Law; Dispute Resolution. 

15.4.1 This Agreement, and any disputes between the Parties related to or arising out of this Agreement, including the Parties’
relationship created hereby, the negotiations for and entry into this Agreement, its conclusion, binding effect, amendment, coverage, termination, or the performance or alleged non-performance of a Party of its obligations under this Agreement (each
a “Dispute”), will be governed by the laws of the State of New York without reference to any choice of law principles thereof that would cause the application of the laws of a different jurisdiction. 

  
 -37- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 15.4.2 In the event of any Dispute, a Party may notify the other Party in writing of
such Dispute, and the Parties will try to settle such Dispute amicably between themselves. If the Parties are unable to resolve the Dispute within *** Business Days of receipt of the written notice by the other Party, such Dispute will be referred
to the Chief Executive Officers of each of the Parties (or their respective designees) who will use their good faith efforts to resolve the Dispute within *** Business Days after it was referred to the Chief Executive Officers. 

15.4.3 Any Dispute that is not resolved as provided in Section 15.4.2, whether before or after termination of this Agreement, will
be resolved by litigation in the courts of competent jurisdiction located in New York, New York. Each Party hereby agrees to the exclusive jurisdiction of such courts and waives any objections as to the personal jurisdiction or venue of such courts.

 15.4.4 Notwithstanding the foregoing, nothing in this Section 15.4 (Governing Law; Dispute Resolution) will limit either
Party’s right to seek immediate temporary injunctive or other temporary equitable relief whenever the facts or circumstances would permit a Party to seek such relief in a court of competent jurisdiction. 

15.5 Notices. All notices or other communications that are required or permitted hereunder will be in writing and delivered personally,
sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided herein), or sent by internationally-recognized overnight courier addressed as follows: 

If to POZEN, to: 
 POZEN Inc.

 1414 Raleigh Road, Suite 400 

Chapel Hill, NC 27517 
 USA 

Attention: President and CEO 

Facsimile: (919) 913-1039 

With a copy to: 
 DLA Piper LLP
(US) 
 51 John F. Kennedy Parkway, Suite 120 

Short Hills, New Jersey 07078 

USA 
 Attention: Andrew P.
Gilbert 
 Facsimile: (973) 520-2575 

  
 -38- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 If to Licensee, to: 

AstraZeneca AB 
 SE-431 83 

Mölndal 
 Sweden 

Attention: Manager Legal Department Mölndal 

Facsimile: +46 31 776 38 71 
 or to such other
address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such communication will be deemed to have been given (i) when delivered, if personally delivered or sent by
facsimile on a Business Day, and (ii) on the second Business Day after dispatch, if sent by nationally-recognized overnight courier. It is understood and agreed that this Section 15.5 (Governing Law; Dispute Resolution) is not intended to
govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. 

15.6 Entire Agreement; Modifications. This Agreement including the Exhibits attached hereto, each of which is hereby incorporated and
made part of in this Agreement by reference, together with that certain side letter between POZEN and AstraZeneca AB, dated September 16, 2013, and the Three-Party Agreement, sets forth and constitutes the entire agreement and understanding
between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. No amendment or modification of this Agreement will be binding upon the Parties unless in writing and duly executed by authorized representatives of both
Parties. 
 15.7 Relationship of the Parties. It is expressly agreed that the Parties’ relationship under this Agreement is
strictly one of licensor-licensee, and that this Agreement does not create or constitute a partnership, joint venture, or agency. Neither Party will have the authority to make any statements, representations or commitments of any kind, or to take
any action, which will be binding (or purport to be binding) on the other. 
 15.8 Waiver. Any term or condition of this Agreement
may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by
either Party hereto of any right hereunder or of claims based on the failure to perform or a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a
similar nature or otherwise. 
 15.9 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be
deemed an original, but all of which together will constitute one and the same instrument. 

  
 -39- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 15.10 No Benefit to Third Parties. The representations, warranties, covenants and
agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns (including Horizon), and they will not be construed as conferring any rights on any Third Party. 

15.11 Further Assurance. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments
and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry
out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

15.12 No Drafting Party. This Agreement has been submitted to the scrutiny of, and has been negotiated by, both Parties and their
counsel, and will be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such terms having been drafted by any Party or its counsel. No rule of strict construction will be
applied against either Party. 
 15.13 Construction. Except where the context otherwise requires, wherever used, the use of any
gender will be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of
this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein means including, without limiting the generality of any description preceding such term. Unless the context indicates otherwise,
the singular will include the plural and the plural will include the singular. Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document refer to such agreement, instrument or other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to any laws refer to such laws as from time
to time enacted, repealed or amended, (c) the words “herein”, “hereof” and “hereunder”, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, and
(d) all references herein to Sections and Exhibits, unless otherwise specifically provided, refer to the Sections and Exhibits of this Agreement. 

15.14 Assignment to Horizon. POZEN acknowledges that, in connection with the Divestiture, AstraZeneca AB will assign this Agreement to
Horizon, effective as of the Amended and Restated Effective Date, and that, notwithstanding Section 15.1, AstraZeneca AB may assign this Agreement to Horizon in connection with the Divestiture without the prior written consent of POZEN. Without
limiting any provision of the Three-Party Agreement, from and after the Amended and Restated Effective Date, all references to “Licensee” in this Agreement, other than references to Licensee in connection with anticipated actions to be
taken by AstraZeneca AB as Licensee in connection with the Divestiture, shall automatically be deemed references to Horizon. 

  
 -40- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 15.15 Amendment and Restatement. This Agreement, together with the ROW Agreement,
constitutes an amendment and restatement of the Original Agreement effective from and after the Amended and Restated Effective Date. All rights or obligations owing under the Original Agreement, or based on facts or events occurring or existing
prior to the Amended and Restated Effective Date, shall be governed by the Original Agreement. As of the Amended and Restated Effective Date, the Original Agreement is hereby amended, supplemented, modified and restated in its entirety as described
herein and in the ROW Agreement. For clarity, in no event shall this Section 15.15 or any other provision in this Agreement be deemed to limit or otherwise affect the agreements made by AstraZeneca AB, Horizon and POZEN in the Three-Party
Agreement or that certain side letter agreement between POZEN and AstraZeneca AB dated September 16, 2013 with respect to each party’s respective liability in connection with the Original Agreement, this Agreement or the ROW Agreement.

 [Remainder of page intentionally left blank. Signature page follows.] 

  
 -41- 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Collaboration and License
Agreement for the United States by their respective authorized representatives as of the date first written above. 
  

			
	        POZEN INC.
		
	        By:	 	 /s/ John R. Plachetka

	        Name:	 	 John R. Plachetka

	        Title:	 	 Chairman, President & CEO

	
	        ASTRAZENECA AB (publ)
		
	        By:	 	 /s/ Jan-Olof Jacke

	        Name:	 	Jan-Olof Jacke
	        Title:	 	President

 [Signature Page to Pozen US Agreement] 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 Schedule 1.43 

Licensed Patents 
  

							
	 SERIAL NUMBER/

FILING DATE
	  	 PUBLICATION NUMBER/ DATE
	  	 TITLE
	  	TERRITORY
	 10/158,216
 May 31, 2002
	  	 US2003069255 A1
 US6926907 B2 / 2005-08-09
 Expires 2023-02-28
	  	Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs	  	U.S.
				
	 11/129,320
 May 16, 2005
	  	US2005249811 A1 / 2005-11-10	  	Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs	  	U.S.

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 Schedule 1.83 

Vimovo Trademarks 
  

											
	 Country
	  	 Mark
	  	 App Date /

Reg Date
	  	App No /
Reg No	  	 Goods
	  	Status
	United States	  	 VIMOVO & Design
 

	  	 App 01-MAY-2009

Reg 01-FEB-2011
	  	App 77726998
 Reg 3914867
	  	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	  	REGISTERED
						
	United States	  	VIMOVO	  	 App 13-FEB-2009
 Reg
05-APR-2011
	  	App 77670350
 Reg 3941225
	  	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	  	REGISTERED0

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 Schedule 8.1.3 

Market Reduction Example 
 For Products
sold in the Territory: 
 *** 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 Schedule 15.1.2 

Form of Consent Agreement 

CONSENT AGREEMENT 

This Consent Agreement (this “Consent”) is made and entered into as of
[                    ] the Effective Date by and between POZEN Inc., a Delaware corporation (“Sponsor”), and [AstraZeneca AB, a
corporation organized under the laws of Sweden][Horizon Pharma USA, Inc., a Delaware corporation] (“Counterparty”). Sponsor and Counterparty are parties to the Amended and Restated Collaboration and License Agreement for [Outside]
the United States effective as of November     , 2013, and any amendments thereto (collectively, the “Agreement”). As of the Effective Date, Sponsor is considering a transaction to sell all or part of its rights
to receive payments under Sections [8.2, 9.6.4 and 12.6.4(b)(i) of the Agreement and paragraph 5 of that certain letter agreement by and among Sponsor, Counterparty and Horizon Pharma USA dated November     , 2013, as well as
certain related information rights under Sections 8.3 and 8.4 of the Agreement and certain recovery rights under Section 8.5 of the Agreement] [8.1 and 9.6.4 of the Agreement and paragraph 5 of that certain letter agreement by and among
Sponsor, Counterparty and AstraZeneca AB dated November     , 2013, as well as certain related information rights under Sections 8.2 and 8.3 of the Agreement and certain recovery rights under Section 8.4 of the Agreement]
(collectively, “Rights”; such contemplated transaction, the “Transaction”). In connection with the Transaction, Sponsor is requesting Counterparty to give its consent under the Agreement to certain matters, as set
forth below. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Agreement. 
 1.
Assignability. Notwithstanding Section 15.1 of the Agreement, Counterparty hereby consents and agrees that in connection the Transaction, Sponsor may sell, assign, pledge as security, contribute, convey, grant or otherwise transfer
(collectively, “assign”) all or any part of the Rights to any one person or entity (whether or not an affiliate of Sponsor) other than a Competitor without the prior written consent of Counterparty in accordance with the terms of
this Consent. In addition, such person or entity (an “Assignee”) of Sponsor may likewise assign such Assignee’s Rights to any one person or entity (whether or not Sponsor or an affiliate of Sponsor) other than a Competitor
without the prior written consent of Counterparty, it being understood and agreed that, all times, there shall only be one single person or entity that holds the Rights (other than Sponsor) and constitutes an “Assignee.”
“Competitor” shall mean any Person, other than Sponsor or its subsidiaries and affiliates, that is in the business of researching, developing or commercializing therapeutics primarily for rheumatoid arthritis and osteoarthritis pain
indications or any company ranked in the top 10 pharmaceutical companies in the United States based on IMS-reported pharmaceutical sales for the preceding calendar year (or any of such company’s subsidiaries or controlled affiliates). 

2. Payment Direction; Reports. Following the consummation of the Transaction, Sponsor shall remain responsible for the performance of
its obligations and the exercise of its rights under the Agreement, however, Counterparty agrees that, upon written notice from Sponsor (or any direct or indirect permitted Assignee contemplated by Section 1 above),

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
Counterparty shall deliver any future payments contemplated by the Agreement, together with any royalty or other reports or statements contemplated by the Agreement (“Reports”)
to the Assignee, in accordance with the directions in such written notice; provided copies of Reports are also simultaneously sent to the Sponsor. 

3. Prospective Assignee Confidentiality. Notwithstanding Section 11 of the Agreement, Counterparty consents and agrees that
Sponsor, in connection with the Transaction, may disclose Confidential Information to its advisors, affiliates, agents, assignees, auditors, bankers, co-investors, contractors, counsel, directors, employees,
financing parties, insurance providers, investors, lenders, managers, members, officers, partners, sublicensees, trustees or other representatives or any third party that has, or proposes to have, an interest (whether direct or indirect) in the
Rights (each, a “Recipient”), provided that each such Recipient (a) is not a Competitor and (b) shall agree to keep such Confidential Information confidential on reasonable and customary terms pursuant to a non-disclosure
agreement between Sponsor (or an affiliate of Sponsor) and such Recipient, which non-disclosure agreement shall, among other things, provide that (i) if such Recipient is not a prospective Assignee identified by the Company or a holder of a
debt or equity interests therein (a “Prospective Assignee”), the term of such non-disclosure agreement shall extend for a period of 24 months from the date of such nondisclosure agreement, (ii) if such Recipient is a
Prospective Assignee, the term of such non-disclosure agreement shall extend for a period of 24 months from the date such Prospective Assignee notifies Sponsor that it ceases to have an interest in the Transaction, (iii) such Recipient shall
use any Confidential Information so disclosed only to evaluate, enter into, monitor or enforce the Transaction, (iv) upon expiration of such non-disclosure agreement, such Recipient promptly shall destroy the Confidential Information or return
the Confidential Information to Sponsor, as directed by Sponsor, provided that in each case an appropriate person within such Recipient’s organization may retain one copy of such Confidential Information subject to the provisions hereof if
required to comply with internal record retention policies or regulatory considerations, and (v) Counterparty shall be treated as a third party beneficiary of such non-disclosure agreement and shall have the right to enforce any provision of
such non-disclosure agreement against such Recipient. For the avoidance of doubt, the term “Confidential Information” shall include unredacted copies of the Agreement, all royalty reports provided by Counterparty pursuant to Section
[8.3.1][8.2.1] of the Agreement, and material notices and correspondence received by Sponsor relating to or involving the Agreement that affect the Rights. 

4. Final Assignee Confidentiality. If Sponsor consummates the Transaction, Sponsor shall cause the Assignee to agree, pursuant to the
definitive documentation for the Transaction, to be bound by confidentiality provisions in substantially the same form and substance as those confidentiality provisions contained in Section 11 of the Agreement (with such Counterparty being
treated as a third party beneficiary of such provisions to the same extent as is contemplated by clause (v) of Paragraph 3 hereof). 

5. Consent Concerning Additional Disclosures. Counterparty hereby consents to and agrees that Sponsor may disclose to its advisors,
including its consulting firm, L.E.K. Consulting (“LEK”), and the Sponsor, its advisors and/or LEK may in turn disclose to Prospective Assignees (who are not Competitors and who have agreed to the confidentiality

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
  

 
obligations set forth in Paragraph 3 hereof) , the following information provided to Sponsor by Counterparty: [(i) the anticipated launch dates of commercial sales of Vimovo by Counterparty in
countries outside the United States;][ (ii) information pertaining to the Counterparty’s new US sales model for Vimovo implemented in 2012;] (iii) historical information relating to the ratio of Vimovo gross sales to net sales[; and
(iv) information relating to Counterparty’s promotional plan for Vimovo and strategy regarding Medicare Part D]. 
 6.
Termination. Unless a definitive agreement with respect to the Transaction has been executed prior to the first anniversary of the Effective Date, this Consent shall automatically terminate as of the first anniversary of the Effective Date.

 Except as supplemented hereby, all terms and provisions of the Agreement shall remain in full force and effect. This Consent may be
executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same agreement. An executed signature page of this Consent delivered by facsimile transmission or in
PDF format via email shall be as effective as an original executed signature page. This Consent shall be governed by the laws of the State of New York without regard to any choice of law principles thereof that would cause the application of the
laws of a different jurisdiction. 
  

			
	POZEN INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[ASTRAZENECA AB (publ)][HORIZON PHARMA USA, INC.]
		
	By:	 	  

	Name:	 	
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]